Способ получения нативного коллагенового продукта

Изобретение относится к косметической и медицинской промышленности, а именно к способу получения коллагенового продукта, характеризующемуся тем, что шкуры щуки, толстолобика, карпа очищают от излишков соединительной ткани, промывают в водном растворе натриевой соли соляной кислоты (NaCl) c концентрацией 5% от массы шкур, после чего промывают в проточной воде и выдерживают сначала в водном растворе сухого порошка горчицы с концентрацией 10% от массы шкур в течение 10 минут, а затем в водном растворе гидрокарбоната натрия (NaHCO3) с концентрацией 2% от массы шкур в течение 15 минут, причем обработанные шкуры измельчают до частиц размером 5-10 мм, промывают в дистиллированной воде при температуре 3-8°С и выдерживают в водном растворе красителя Е-171 (TiO2 - диоксид титана) с концентрацией 10% от массы шкур в течение 1 часа, затем промывают в дистиллированной воде при температуре 3-8°С и выдерживают в водном растворе молочной кислоты (C3H6O3, CH3CH(OH)COOH) с концентрацией 1% от массы шкур ...

БЕЛОКСОДЕРЖАЩИЕ ПЕНОМАТЕРИАЛЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ

Изобретение относится к полиуретановому пеноматериалу, способу получения полиуретанового пеноматериала, премиксу для получения полиуретанового материала и изделию, содержащему пеноматериал. Полиуретановый пеноматериал представляет собой продукт реакции смеси: (а) реагент на основе изоцианата; (b) необязательное реагирующее с изоцианатом соединение и белоксодержащую композицию, способную уменьшать плотность полиуретанового пеноматериала по меньшей мере на 5% относительно полиуретанового материала, полученного из той же самой смеси, но лишенного белоксодержащей композиции. Технический результат - получение возобновляемых, менее дорогостоящих и более благоприятных в отношении окружающей среды агентов, которые могут модулировать свойства пеноматериалов. 4 н. и 76 з.п. ф-лы, 11 табл., 19 ил., 14 пр.

Способ получения коллагенового продукта

Изобретение относится к перерабатывающей и косметической промышленности, а именно к способу получения коллагенового продукта, характеризующемуся тем, что принимают шкуры пресноводных рыб, таких как толстолобик, карп, белый амур, сазан, очищают их ручным или машинным способом от чешуи, прирезей мышечной ткани, плавников и механических загрязнений, промывают в машинах барабанного типа в растворе хозяйственного мыла в течение 30 мин, а затем в воде - до отсутствия остатков мыла, промытые шкуры подвергают перекисно-щелочной обработке, для чего шкуры заливают смесью пероксида водорода с массовой концентрацией 3% и гидроксида натрия с массовой концентрацией 3% и выдерживают в течение 1,5-2 часов при температуре 20-25°С и гидромодуле 1:4, обработанные таким образом шкуры промывают в проточной воде при температуре 8-12°С в течение 10-15 мин, затем шкуры заливают раствором лимонной кислоты с массовой концентрацией 6% и выдерживают в течение 6 суток, полученную массу гомогенизируют, упаковывают в ...

СПОСОБ ПРИГОТОВЛЕНИЯ КОЛЛАГЕНОВОГО ПОРОШКА МЕДИЦИНСКОГО НАЗНАЧЕНИЯ ИЗ КОЖИ ЖИВОТНЫХ

Настоящее изобретение относится к области медицины и раскрывает способ производства коллагенового порошка медицинского назначения из кожи животных, включающий механическое освобождение жирных остатков из коллагенового сырья, его промывку, обработку коллагенового сырья щелочным элементом, обработку сырья кислотой и последующую промывку водой, отжим и промывание материала водой, удаление воды из полученного матричного продукта и сушку матрицы в растянутой форме для получения мембраны, при этом в качестве исходного сырья используют кожу кролика, а полученную в результате обработки мембрану, после сушки шлифуют с двух сторон, после чего подвергают шоковой заморозке в жидком азоте, затем, в замороженном состоянии, измельчают в мельнице, а полученный коллагеновый порошок стерилизуют альфа излучением. Техническим результатом настоящего изобретения является гипоаллергенность и хорошая приживляемость получаемого коллагенового порошка. 1 пр.

СПОСОБ ПОЛУЧЕНИЯ ВОЛОКНИСТОГО ПОРИСТОГО МАТЕРИАЛА

Способ касается получения волокнистого пористого материала, который может быть использован при изготовлении обуви, кожгалантерейных изделий и обивочных материалов. Способ включает приготовление коллагеновой дисперсии, состоящей из коллагенсодержащих отходов кожевенного производства, латекса и воды. В качестве отходов кожевенного производства используют кожевенный порошок и продукты растворения коллагена при определенном соотношении компонентов. Затем осуществляют замораживание полученной дисперсии с последующим ее размораживанием и сушкой полученного материала. Способ позволяет получить волокнистый пористый материал с высокими физико-механическими свойствами. 2 табл.

СПОСОБ ПОЛУЧЕНИЯ КОЛЛАГЕНСОДЕРЖАЩЕГО МАТЕРИАЛА

Сущность изобретения: дубленые отходы кожевенного производства измельчают, смешивают их с жидким компонентом, вводят в полученную суспензию связующую добавку и смешивающий агент до образования коллагенсодержащей смеси, замораживают смесь путем отвода тепла при значении числа Био не менее 0,2, выдерживают замороженную смесь с сохранением в ней жидких микрофаз в течение не менее 20 мин. 3 ил.

СПОСОБ ИЗГОТОВЛЕНИЯ ИСКУССТВЕННОЙ КОЖИ

Сущность изобретения: отходы натуральной кожи измельчают, увлажняют и равномерным слоем раскладывают на покрытии с ячеистой структурой, наносят слой связующего и слой мелкодисперсного ферромагнитного порошка, воздействуют на сформованные слои постоянным и импульсным магнитным или электромагнитным полем, прессуют полученный слой и проводят термообработку. Воздействие полем заканчивают после выхода ферромагнитного порошка на основание покрытия. На увлажненный слой измельченной кожи можно наложить слой ворса.

СПОСОБ ПОЛУЧЕНИЯ ЛИСТОВОГО КРИОСТРУКТУРИРОВАННОГО КОЛЛАГЕНСОДЕРЖАЩЕГО ГУБЧАТОГО МАТЕРИАЛА И ЛИСТОВЫЕ КРИОСТРУКТУРИРОВАННЫЕ КОЛЛАГЕНСОДЕРЖАЩИЕ ГУБЧАТЫЕ МАТЕРИАЛЫ

Использование: для получения материалов медицинского назначения, в частности перевязочных материалов и фильтрующих материалов для фильтрования жидкостей и газов. Сущность изобретения: промытое измельченное коллагенсодержащее сырье животного происхождения подвергают щелочно-солевой обработке водным раствором, содержащим 5-9 мас.% NaOH и 9-11 мас.% Na2SO4, при жидкостном модуле обработки, равном 2-5, в течение 24-48 час, после промывки водой коллагенсодержащее сырье дополнительно подвергают выдержке в 0,5-1,5 М водном растворе кислоты при жидкостном модуле обработки, равном 1,5-3, с последующей промывкой водой и разволокнением коллагенсодержащего сырья в водной среде, затем получают гомогенную пасту коллагена с рН 3-5,5 при обработке волокнистой массы водным 0,5-3%-ным раствором щелочи при массовом соотношении волокнистой массы к водному 0,5-3%-ному раствору щелочи, равном от 1:0,5 до 1:2,5, с последующим доведением рН до 3-5,5 добавлением кислоты, вводят физиологически приемлемый сшивающий ...

СПОСОБ УТИЛИЗАЦИИ ОТХОДОВ, СОДЕРЖАЩИХ ЖИВОТНЫЕ БЕЛКИ, И УСТРОЙСТВО ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ

Изобретение относится к утилизации отходов, содержащих животные белки. Для утилизации отходов, содержащих животные белки, смешивают отходы, воду и щелочь в соотношении 1:(1,8-2,0):(0,09-0,46), приготовленную смесь подвергают водно-термической обработке при температуре 120-180°С в течение 25-90 мин с получением жидкого гидролизата. В зависимости от соотношения параметров процесса получают смесь аминокислот, или их смесь с низкомолекулярными белками, или низкомолекулярные белки. Предложено устройство для реализации данного способа, которое содержит реактор 1 с герметично закрывающейся крышкой 6, который связан двумя трубопроводами 8 и 9 с расположенным над ним расширителем-холодильником 2, декантатор 15 с фильтром 4, приемник 5 продуктов утилизации и адсорбер 17. 2 н. и 10 з.п. ф-лы, 3 ил.

КОЖЕПОДОБНЫЙ МАКРОПОРИСТЫЙ МАТЕРИАЛ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Кожеподобный материал и способ его получения относятся к макропористым коллагенсодержащим материалам, а именно к материалам, получаемым путем переработки коллагенсодержащих дисперсий, обладающих комплексом физико-механических и гигиенических свойств, обычно присущих коже, вырабатываемой из шкур животных, и могут быть использованы в кожевенной промышленности. Кожеподобный макропористый материал содержит коллаген, дубленые кожевенные волокна и полимер, обладающий свойствами соединять коллагеновые волокна в единую структуру при его доле по отношению к суммарному количеству коллагена и кожевенных волокон в интервале от 3 до 30 мас.%. Способ изготовления кожеподобного макропористого материала предусматривает его получение замораживанием, последующую сушку под вакуумом до остаточной влажности не более 12%, выдержку при комнатной температуре в течение суток, обработку водной полимерной дисперсией, обеспечивающей соединение коллагеновых волокон в единую структуру, и дополнительную сушку под вакуумом ...

СПОСОБ ПОЛУЧЕНИЯ КОЛЛАГЕНСОДЕРЖАЩЕГО МАТЕРИАЛА

Сущность изобретения: из недубленых кожевенных отходов приготавливают коллагеновый раствор, из дубленых кожевенных отходов - пасту с размером частиц твердого вещества 0,2-0,6 мм. Раствор и пасту смешивают в течение 1-5 ч при температуре не выше 15°С до получения однородной массы, имеющей 0,1-2 мас. % недубленого коллагена, 0,3-10 мас.% дубленого коллагена и рН 2,6-5,0. Массу фильтруют до размера входящих в нее частиц 0,2-0,6 мм, охлаждают до температуры 0-5°С, добавляют сшивающий агент в количестве 0,15-7,0 мас.% и гомогенизируют полученную смесь при температуре не выше 5°С. Производят замораживание, при котором температуру смеси снижают от минус 14 до минус 75°С в течение 0,1-2,0 ч и выдерживают в замороженном состоянии при температуре от минус 2 до минус 20°С в течение 4-24 ч. Далее производят размораживание и выдержку полученного полимерного материала на воздухе при комнатной температуре во влажном состоянии без нагрузки в течение 6-12 ч, нагрев до 85-105°С, охлаждение до комнатной температуры ...

СПОСОБ ПОЛУЧЕНИЯ БЕЛКОВОГО ГИДРОЛИЗАТА

Способ получения белкового гидролизата, включающий промывку сырьевых отходов и щелочно-пероксидную обработку в водном растворе гидроксида натрия и пероксида водорода, отличающийся тем, что щелочно-пероксидную обработку ведут при расходе гидроксида натрия и пероксида водорода 2,0-3,0% и 1,6-1,8% от массы отходов соответственно, после чего дополнительно производят гидролиз отходов ферментным препаратом Савиназа, полученным из генетически модифицированной культуры Bacillus, в присутствии сульфата аммония при их расходе соответственно 0,2-2,0% и 1,3-1,5% от массы отходов.

ПОЛИМЕР ЖЕЛАТИНА, ПОЛУЧЕННЫЙ ИЗ МОРСКИХ ПРИРОДНЫХ ИСТОЧНИКОВ, АДАПТИРОВАННЫХ К ХОЛОДУ, И ЕГО ИСПОЛЬЗОВАНИЕ

КОМПОЗИЦИЯ ДЛЯ ПОЛУЧЕНИЯ ЛИСТОВОГО КРИОСТРУКТУРИРОВАННОГО КОЛЛАГЕНОВОГО КОЖЕПОДОБНОГО МАТЕРИАЛА

Предложена композиция для получения криоструктурированного кожеподобного материала в виде листа из отходов дубленой и недубленой кожи с применением в качестве сшивающего агента аминоальдегидной смолы или карбоксилсодержащего сополимера заданной формулы при установленном соотношении компонентов.

Рекомбинантные желатины

... 1. Композиция, включающая рекомбинантный желатин. 2. Рекомбинантный желатин, имеющий молекулярный вес, выбранный из группы, состоящей из около 5 кДа, около 8 кДа, около 9 кДа, около 14 кДа, около 16 кДа, около 22 кДа, около 23 кДа, около 36 кДа, около 44 кДа и около 65 кДа. 3. Рекомбинантный желатин, имеющий молекулярный вес, в диапазоне, выбранном из группы, состоящей из около 0-50 кДа, около 10-30 кДа, около 30-50 кДа, около 10-70 кДа, около 50-70 кДа, около 50-100 кДа, около 100-150 кДа, около 150-200 кДа, около 200-250 кДа, около 250-300 кДа и около 300-350 кДа. 4. Рекомбинантный желатин, имеющий молекулярный вес выше, чем 300 кДа. 5. Рекомбинантный желатин, имеющий прочность по Блуму, выбранную из группы, состоящей из 50, 100, 150, 200, 250 и 300. 6. Рекомбинантный желатин, имеющий прочность по Блуму между 0 и 100. 7. Композиция по п.1, где рекомбинантный желатин является частично гидроксилированным. 8. Композиция по п.1, где рекомбинантный желатин имеет процент гидроксилирования, ...

НОВЫЕ БИОПОЛИМЕРЫ, ПОЛУЧЕННЫЕ ОБЛУЧЕНИЕМ В ТВЕРДОЙ ФАЗЕ В АТМОСФЕРЕ НЕНАСЫЩЕННЫХ ГАЗОВ

... 1. Способ модификации встречающегося в природе биосовместимого биополимера, где указанный способ включает обработку указанного биополимера в твердом или сухом состоянии источником ионизирующего излучения в присутствии опосредствующего газа и отжиг полученного продукта в отсутствии кислорода при температуре от около 40° до 120°C, с последующим удалением всего оставшегося опосредствующего газа. 2. Способ по п.1, где источником ионизирующего излучения является радиоактивный изотоп, излучающий γ-лучи, рентгеновские лучи или излучение высокой энергии, создаваемое ускорителем электронов. 3. Способ по п.2, где доза ионизирующего излучения, которой обрабатывают биополимер, составляет от около 1 до 50 кГр. 4. Способ по п.2, где радиоактивным изотопом является60Со. 5. Способ по п.2, где источником излучения служит электронный генератор мощностью от 250 КэВ до 10 МэВ. 6. Способ по п.1, где опосредствующим газом является незамещенный алкеновый или алкиновый газ, которым является этилен, пропилен или ...

СПОСОБ ПОЛУЧЕНИЯ ПОРИСТОГО МАТЕРИАЛА

... 1. Способ получения пористого материала, включающий: образование дисперсной системы, содержащей жидкую дисперсионную среду, способную к кристаллизации, и дисперсную фазу, включающую латекс и коллагенсодержащие отходы кожевенного производства; замораживание образованной дисперсной системы при температуре, достаточной для ее структурирования; последующее формование структурированной дисперсной системы и ее замораживание до полного отверждения дисперсной системы, которая после размораживания и сушки представляет собой целевой продукт заданной формы, отличающийся тем, что при образовании дисперсной системы используют названные коллагенсодержащие отходы, дополнительно предварительно подвергнутые титрованию щелочью до рН 10-12, при этом перед замораживанием, обеспечивающим структурирование, дисперсную систему охлаждают до температуры, равной 2 - 4oС, а в процессе этого последующего замораживания осуществляют насыщение воздухом дисперсной системы до изменения средней концентрации дисперсной фазы ...

Способ изготовления ганалита

Способ получения белкового сорбента

Изобретение относится к области химии полимеров и может быть использовано в аффинной хроматографии и разделительной ионообменной хроматографии. Изобретение позволяет создать белковый сорбент на основе кератинсодержащего сырья, обладающий емкостью по ионам ртути 176- 196 мг/r сорбента, что достигается обработкой кератинсодержащего сырья (ОСТ 10-02-01-06-87) до растворения гидросульфита натрия в водной среде в присутствии 5,5 ±0,2% сульфанола от массы и высаживанием частиц сорбента при диспергировании в осадительную смесь, состоящую из этилового спирта или ацетона и концентрированной соляной кислоты, взятых в объемном соотношении (3-5): 1.

Способ получения растворимых в воде продуктов распада кератина

Способ получения пластических масс

Способ получения желирующих продуктов из морских водорослей

Способ получения ионообменных сорбентов

PROCESS FOR CHEMICAL DEFIBRATING LEATHER BOARD CUTTING

PROCESS FOR PREPARATION PROTEIN TANNING LIQUOR FOR NATURAL LEATHER

Биополимерная композиция

Композиция для получения волокнисто-пористого материала

Использование искусственные волокнисто-пористые материалы Сущность изобретения: композиция содержит следующие компоненты мае ч: продукт растворения 4.5 - 5.0 мае ч. коллагена в 100 мае ч 0,1 М водного раствора 0-фосфорной кислоты 25.0 - 50.0; глутаровый альдегид 0,7 - 1.0; вода 5625 - 37,5; отходы дубленых кож 12.5 - 18.75 1 табл ...

Способ получения биологически активны полифенолов из прополиса

Способ получения белкового поверхностно-активного вещества для кож

Изобретение касается поверхностно-активных веществ (ПАВ), в частности белкового (Б-ПАВ), используемого для кож в легкой промышленности. Улучшение качества В-ПАВ и повышение их растворимости, смачивающей . способности и придание им протеолити-. ческой активности достигается проведением термической обработки обеззо- ленных кожевенных отходов кожевенного производства в присутствии другого гидролизующего реагента - отхода мыловаренного производства, взятого в количестве 40-80Z от массы кожепеп- ных отходов. Последние содержат, мас.%: натриевые мыла предельных и непредельных жирных кислот фракции - С , гидроксид натрия 2-4, - остальное. Б-ПАВ обладают фер- метативньми свойстваьш и широкой гаммой свойств. Позволяющих увеличить прочность кожи, уплотнить лицевой слой, изменить эластичные свойства кожи. Кроме того, дифильный характер Б-ПАВ положительно сказывается как на сохранении гигиеничности, так и на снижении водопроницаемости кожи. 1 табл. t,. схэ СП с j: со «./i ...

Способ получения привитых сополимеров

Способ использования отходов галалита

СПОСОБ ПОЛУЧЕНИЯ ГАЛАЛИТА

Способ получения белкового гидролизата

Сущность изобретения: белковый гид- ролизат получают термической обработкой дубленых отходов кожевенного производства в присутствии отхода щелочной очистки дизельного топлива в количестве 170-250% от массы кожевенного сырья, следующего состава, мас.%: дизельное топливо 1-10; нафтенаты натрия 1-20; гидроксид натрия 0.1-2,1 и вода остальное. Обработку осуществляют в присутствии свободной щелочи в количестве 7-10% от массы кожевенных отходов . 1 табл.

Способ получения белкового гидролизата

Сущность изобретения: белковый гид- ролизат получают обработкой гольевых отходов кожевенного производства в присутствии отхода щелочной очистки дизельного топлива в количестве 50-200% от массы кожевенного сырья, следующего состава , мас.%: дизельное топливо Т-10; наф- тенаты натрия 1-20; гидроксид натрия ОИ-2,1 и вода остальное. 1 табл.

Schönungsmittel auf Basis von Kollagen und Verfahren zu deren Herstellung

HYDROGEL AUF BASIS VON ALBUMIN

Polyäthylenglycolprotein Konjugate

DURCH PFROPFUNG VON MERKAPTOGRUPPEN MODIFIZIERTE KOLLAGENPEPTIDE, EIN VERFAHREN ZU IHRER HERSTELLUNG UND IHRE ANWENDUNG ALS BIOMATERIALIEN

Verfahren zur Herstellung von Kollagenfasern

MODIFIZIERTES HAEMOGLOBIN ENTHALTENDER BLUTERSATZ

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN AUS GEMISCHTEN SALZEN VON SULFOGLYKOPEPTIDEN MIT METALLBASEN UND ORGANISCHEN BASEN

QUERVERNETZTE KOLLAGEN-MATRICES UND METHODEN ZU DEREN HERSTELLUNG

TRÄGER MIT FESTEM FIBRINOGEN UND THROMBIN

Intramolecular transesterification of material, especially plant extract, containing cyclic polyhydroxy compounds, e.g. to prepare bioactive natural products, carried out at elevated temperature and pressure

Intramolecular transesterification of starting materials containing cyclic polyhydroxy compounds (e.g. phenylethanoids) is carried out at a pressure of 1-20 x 103> Pascals and a temperature of 40-250[deg]C, using an autoclave, sealed glass tube, distillation apparatus, extractor (e.g. Soxhlet) or perforator as apparatus. ACTIVITY : Antiinflammatory. MECHANISM OF ACTION : None given in the source material.

Methods for the preparation of sulphonaphthenic derivatives of albumins

Sulphonaphthenic derivatives of albumins are prepared by treating naturally occurring or artificially prepared aqueous solutions of albumins with a sulphonation product of crude petroleum naphtha, or fractions thereof, containing naphthenic hydrocarbons and removing the resulting product. Preferably, the aqueous albumin solution is first acidified, to an extent insufficient to precipitate the albumin, whereby the amount of sulphonated naphthenic hydrocarbon required is reduced. Albumin solutions mentioned are blood in the whole, defibrinated or separated form and glutin solutions and in the latter case separation of several fractions of glutin derivatives is possible. The products are soluble in alkali and react with organic bases; they may be used in glues (see Group V) and as fillers in plastics, especially in phenolformaldehyde plastics. Examples describe the preparation of sulphonaphthenic derivatives of blood by treating blood, alone or acidified with sulphuric or acetic acid, with ...

RESIN ADDUCTS WITH BIOLOGICALLY ACTIVE SUBSTRATES

... 1459507 Three dimensional terpolymer resins; insolubilized enzymes CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT 19 Feb 1974 [28 Feb 1973] 7513/74 Headings C3P and C3H A three dimensional resin, to which enzymes or other biologically active substrates may be covalently bound, comprises units of (A) maleic anhydride, citraconic anhydride, itaconic anhydride or a mixture of these; (B) hydrophobic aromatic vinyl and divinyl monomers; and (C) one or more copolymerizable aliphatic ,#- olefinically unsaturated monocarboxylic acids, the ratio and nature of units (A), (B) and (C) being such that the resin is capable of binding an enzyme in aqueous medium at pH 5-9 without substantial denaturation or inactivation. The monomers preferably involved are (B) styrene or divinylbenzene and (C) acrylic acid optionally substituted with one or more 1-3C alkyl groups, e.g. acrylic or methacrylic acid. Enzymes, e.g. trypsin or penicillin acylase may be bound to the resin by contacting the enzyme in aqueous ...

A process for treating collagen, and dried collagen produced by that process

A dried collagen product is produced by hydrolysing tissue material partially to produce collagen having a 40% to 99% by weight moisture content. This collagen is dried, preferably by freeze drying while maintaining its temperature below 40 DEG C, and the dried product is comminuted. The dried product can be re-hydrated to produce collagen finings.

Blood substitute containing modified hemoglobin

A novel modified hemoglobin was prepared. The hemoglobin is coupled with a polyalkylene glycol or its derivative, and the products are useful as a blood substitute. The oxygen-carrying capacity of this hemoglobin is nearly equal to that of a native hemoglobin, and the residence time in the circulation is satisfactorily long.

METHOD AND APPARATUS FOR HYDROLYZING KERATINACEOUS MATERIAL

PROTEIN-SILICONE COPOLYMERS

INTERMEDIATES USEFUL IN THE SYNTHESIS OF CHEMILUMINESCENT NAPHTHALENE-1,2-DICARBOXYLIC ACID HYDRAZIDE-LABELLED CONJUGATES

Method and apparatus for preparing an acellular red blood cell substitute.

A highly conserved, immunologically accessible antigen at the surface of Neisseria meningitidis organisms. Immunotherapeutic prophylactic and diagnostic compositions and methods useful in the treatment, prevention and diagnosis of Neisseria meningitidis diseases. A proteinase K resistant Neisseria meningitidis surface protein having an apparent molecular weight of 22 kDa, the corresponding nucleotide and derived amino acid sequences (SEQ ID N0:l, NO:3, NO:5, and NO:7: SEQ ID NO:1, NO:4, NO:6, and N0:8), recombinant DNA methods for the production of the Neisseria meningitidis 22 kDa surface protein, and antibodies that bind to the Neisseria meningitidis 22kDa surface protein.

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Meth d and appar tus f r pre aring an acellular red blood cell substitute

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Novel macrocyclic inhibitors of hepatitis c virus replication

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Method and apparatus for preparing an acellular red blood cell substitute

“Combined protein and of polyethylene glycol”.

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Novel macrocyclic inhibitors of hepatitis c virus replication

Meth d and appar tus f r pre aring an acellular red blood cell substitute

Novel macrocyclic inhibitors of hepatitis c virus replication

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.

PROCEDURE FOR THE ADJUSTMENT OF BIOLOGICALLY ACTIVE PROTEIN TO PP

USE OF WITH PEPSIN OF TREATED GEL AS STABILIZER FOR INJECT-CASH MATERIALS CONTAINING PROTEIN TRACES

THERMOPLASTICS ON THE BASIS OF SOY BEANS AS BIOLOGICAL MATERIALS

PROCEDURE FOR THE CLEANING OF PROTEINS

VERFAHREN ZUR HERSTELLUNG VON MODIFIZIERTER GELATINE MIT ERNIEDRIGTEM GELSCHMELZPUNKT

TEILCHENFÖRMIGE CELLFREE FABRIC MATRIX

KOSMETISCHES MITTEL

PROCEDURE FOR THE PRODUCTION OF KOLLAGEN HYDROLYSATES

PROCEDURE FOR THE HYDROLYSIS OF CASEIN

PROCEDURE FOR THE PRODUCTION OF WASSERLOESLICHEM, POLYMERIZING, INTERCONNECTION STROMAFREIEM HAEMOGLOBIN

PROCEDURE FOR THE PRODUCTION OF THERMOPLASTIC PLASTICS

POLYPEPTID POLYSILOXAN COPOLYMERS

WATER-SOLUBLE, BIOLOGICAL DEGRADABLE COPOLYMERS ON PP BASIS AND THEIR USE

PROCEDURE FOR THE PRODUCTION OF KOLLAGEN HYDROLYSATES

PROCEDURE FOR INTERLACING FILMS, FOILS AND BULK MATERIAL

KNOCHENKOLLAGENMATRIX FOR IMPLANTS.

PROCEDURE FOR THE IMMOBILIZATION OF LOOSENING OF PROTEIN MATERIALS.

PROCEDURE FOR THE NETWORKING OF KASEINFILMEN IN THE LEATHER SIDE DRESSING.

HEMOGLOBIN COMPOSITION AND YOUR USE.

PROCEDURE FOR THE NETWORKING FABRICS OR BIOLOGICAL MATERIALS MANUFACTURED BY KOLLAGEN BY INTRODUCTION OF GROUPS OF AZIDES AND BY THIS PROCEDURE.

KOLLAGENPRAEPARATE, PROCEDURE FOR YOUR PRODUCTION AND YOUR USE IN HUMANUND VETERINARY MEDICINE.

COSMETIC MEANS

INTERLACE-CASH KOLLAGENDERIVATE, PROCEDURES FOR YOUR PRODUCTION AND YOUR USE FOR THE PRODUCTION OF BIOLOGICAL MATERIALS

DERIVATIVE OF KERATIN, PROCEDURE FOR ITS PRODUCTION AND THIS CONTAINING TREATMENT COMPOSITION.

ADHESIVE COMPOSITIONS FROM VEGETABLE PROTEIN

PROCEDURE FOR THE PRODUCTION OF A KOLLAGEN OF SPONGE; EXTRACTION DEVICE OF A PART OF A KOLLAGEN SPONGE AND AN EXTENDING KOLLAGEN SPONGE

PROCEDURE FOR THE PRODUCTION OF A THERMOPLASTIC PROCESSABLE COMPOUND MATERIAL FROM CHITIN

Selfresponsible coat means

Procedure for the production of modified all gene materials

WATER-SOLUBLE ACTIVE SULFONES OF POLYETHYLENGLYCOLEN

MEANS AND PROCEDURE FOR THE USE IN THE INHIBITION OF CELL DEATH AND FOR THE ADMINISTRATION OF AN ACTIVE SUBSTANCE INTO A CELL

Photographic material

Methods of processing recombinant procollagen

A method of generating atelocollagen is disclosed. The method comprises contacting a human telopeptide-comprising collagen with a protease selected from the group consisting of neutrase, subtilisin, ficin recombinant human trypsin and recombinant human pepsin, wherein said human telopeptide-comprising collagen is expressed in a non-animal cell, thereby generating the atelocollagen. Compositions comprising the atelocollagen generated thereby are also disclosed.

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Implantable material and a method for the preparation thereof

A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.

Methods of Modifying Agricultural Co-Products and Products Made Therefrom

In a method of producing a polymer composite, a polymer is provided in a liquid state such as a molten state. A plant material, such as soymeal, is provided that includes protein and carbohydrate. A reactive protein denaturant is also provided. A dispersion of the plant material and the reactive protein denaturant is formed in a matrix of the liquid polymer. The plant material is reacted to bond with the reactive protein denaturant, and the reactive protein denaturant is reacted to bond with the polymer. The polymer is solidified to produce the polymer composite.

Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one liner covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by said linker. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a linker to a polysaccharide to obtain an intermediate and by conjugating said intermediate to a metal to form a polysaccharide conjugate. This conjugate has a higher relaxivity, so it is suitable to be used as a contrast medium for hybrid camera.

Crosslinked Hydrogels and Related Method of Preparation

The present invention provides a method of manufacturing a hydrogel comprising the step of crosslinking a biopolymer using a carbodiimide crosslinker of Formula I wherein at least one of R 1 and R 2 is a functional group that is a bulky organic functional group. R 1 and R 2 can each independently be an optionally substituted saturated or unsaturated functional group selected from the group consisting of an alkyl, a cycloalkyl, a heterocyclic, and an aryl. The bulky organic functional group will slow down the crosslinking reaction of carbodiimide due to the steric effects and/or electronic effects, in comparison to a crosslinking reaction using EDC. Also provided are the hydrogels and ophthalmic devices prepared using the method of the invention and uses thereof.

Cross-linked compositions

Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).

Cosmetic sponge and method for providing a cosmetic sponge

This invention relates to a cosmetic sponge and a method of providing a cosmetic sponge incorporating a non-denatured collagen and other additives for skin care, cleaning, and cosmetic application.

Phase separated composite

A composite is disclosed. The composite comprises a first conjugate of a polymer and a first phenol-containing moiety, and a second conjugate of a gelatin or collagen and a second phenol-containing moiety, wherein the polymer is selected so that the first conjugate is less cell-adhesive than the second conjugate, at least one of the first and second conjugates is crosslinked to form a matrix, and the composite comprises discrete regions that are rich in one of said first and second conjugates. A method of forming such composite is also disclosed. The method comprises mixing precursors for the first and second conjugates in a solution for forming said composite, and dispersing a catalyst in the solution to catalyze crosslinking of at least one of the first and second conjugates to form the matrix. The composite may be used to grow cells.

WHEAT GLUTEN BASED COMPOSITIONS AND ARTICLES MADE THEREFROM

Disclosed herein are wheat gluten based compositions having improved mechanical properties as well as articles formed therefrom, and methods of making the same. More particularly, the compositions also include fibrous reinforcing material and may be formed into a variety of products, including but not limited to particle board. 2. The composition of claim 1 , comprising about 5% to about 15% wheat gluten.3. The composition of claim 1 , comprising about 5% to about 10% wheat gluten.4. The composition of claim 1 , comprising about 1% to about 5% wheat gluten.5. The composition of claim 1 , comprising about 5% to about 15% denaturant.6. The composition of claim 1 , comprising about 5% to about 10% denaturant.7. The composition of claim 1 , wherein the denaturant is selected from the group consisting of guanidine hydrochloride claim 1 , urea claim 1 , sodium dodecyl sulfate claim 1 , ammoniumtetramethylenedithiocarbamate claim 1 , ammoniumpyrrolidonedithocarbamate claim 1 , tetramethylammoniumbromide claim 1 , pentaalkylammoniumbromidehexaethyl surfactants claim 1 , and combinations thereof.8. The composition of claim 1 , wherein the denaturant is urea.9. The composition of claim 1 , comprising about 7% to 13% moisture content.10. The composition of claim 1 , further comprising one or more additive selected from a wax claim 1 , an antimicrobial claim 1 , or combinations thereof.11. A board material comprising:about 15% or less of wheat gluten;about 0.5% to about 10% denaturant;less than about 15% moisture; and70% to about 90% wood particles.12. The board material of claim 11 , comprising about 5% to about 10% wheat gluten.13. The board material of claim 11 , comprising about 1% to about 5% wheat gluten.14. The board material of claim 11 , comprising about 5% to about 15% denaturant.15. The board material of claim 11 , comprising about 5% to about 10% denaturant.16. The board material of claim 11 , wherein the denaturant is selected from the group consisting of guanidine ...

IMPLANTABLE HYALURONIC ACID/COLLAGEN COMPOSITIONS

Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products. 1. A crosslinked macromolecular matrix comprising:a hyaluronic acid component;a collagen component derived from collagen type I or collagen type III;wherein the hyaluronic acid component is crosslinked to the collagen component by a crosslinking component; andwherein the crosslinking component comprises a plurality of crosslink units, wherein at least a portion of the crosslink units comprise an ester bond or an amide bond.2. The crosslinked macromolecular matrix of claim 1 , having a weight ratio of the hyaluronic acid component to the collagen component of about 0.5 to about 7.3. The crosslinked macromolecular matrix of claim 1 , wherein the hyaluronic acid component has an average molecular weight of about 500 claim 1 ,000 daltons to about 10 claim 1 ,000 claim 1 ,000 daltons.4. The crosslinked macromolecular matrix of claim 1 , further comprising an aqueous liquid comprising water claim 1 , sodium chloride at a concentration of about 100 mM to about 200 mM claim 1 , potassium chloride at a concentration of about 2 mM to about 3 mM claim 1 , and phosphate buffer at a concentration of about 5 mM to about 15 mM claim 1 , wherein the pH of the liquid is about 7 to about 8.5. A composition comprising:a hyaluronic acid;a collagen;a water-soluble coupling agent; and 'wherein the composition is an aqueous solution.', 'a buffer;'}6. The composition of claim 5 , further comprising an activating agent comprising a triazole claim 5 , a fluorinated phenol claim 5 , a succinimide claim 5 , or a sulfosuccinimide.7. The composition of claim 5 , wherein the hyaluronic acid component has an average molecular weight of about 1 claim 5 ,000 claim 5 ,000 daltons to about 5 claim 5 ,000 claim 5 ,000 daltons.8. The composition of claim 5 ...

CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. 1. A soft tissue augmentation product comprising:a forming component comprising a hydrogel having a form suitable for augmenting human soft tissue by injecting or implanting the forming component into the human tissue; and 'wherein the hydrogel comprises water, and a crosslinked macromolecular matrix comprising:', 'a label comprising instructions to inject or implant the forming component into the human tissue;'}a hyaluronic acid component; and 'wherein the hyaluronic acid component is crosslinked to the collagen component by an ester bond or an amide bond.', 'a collagen component;'}2. The product of claim 1 , wherein crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid component to the collagen component of about 1 to about 7.3. The product of claim 1 , wherein crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid component to the collagen component of about 3.4. The product of claim 1 , wherein crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid component to the collagen component of about 5.5. The product of claim 1 , wherein crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid component to the collagen component of about 7.6. The product of claim 1 , wherein the hyaluronic acid is about 0.2% to about 2.5% of the weight of the hydrogel and the collagen component is about 0.05% to about 1.2% of the weight of the hydrogel.7. The product of claim 1 , wherein the hydrogel further comprises human adipose tissue.8. The product of claim 1 , wherein the hydrogel has a collagen concentration of about 3 mg/mL to about 12 mg/mL.9. The product of wherein the hydrogel has ...

METHODS OF MANUFACTURING PLASTIC MATERIALS FROM DECOLORIZED BLOOD PROTEIN

The present disclosure provides methods for manufacturing plastic materials from decolorized blood protein. The method includes the following steps: contacting the blood protein an oxidizing agent to form a blood protein composition that includes unreacted oxidizing agent; removing at least a portion of the unreacted oxidizing agent from the blood protein composition to form a decolorized blood protein composition; and treating the decolorized blood protein composition in the presence of a plasticizer with sufficient pressure and temperature to form the plastic material. The present disclosure also provides a plastic material including a blood protein residue having a percent whiteness of 35%-100% and a plasticizer. 1. A method of decolorizing blood protein and manufacturing the decolorized blood protein into a plastic material , the method comprising:contacting the blood protein with an oxidizing agent to form a blood protein composition that includes unreacted oxidizing agent;removing at least a portion of the unreacted oxidizing agent from the blood protein composition to form a decolorized blood protein composition; andtreating the decolorized blood protein composition in the presence of a plasticizer with sufficient pressure and temperature to form the plastic material.2. The method of claim 1 , further comprising contacting the decolorized blood protein composition with a denaturing agent prior to the treating step.3. The method of claim 1 , wherein the blood protein is selected from the group consisting of whole blood claim 1 , isolated red blood cells claim 1 , serum claim 1 , hemoglobin claim 1 , blood meal claim 1 , spray dried hemoglobin claim 1 , and mixtures thereof.4. The method of claim 1 , wherein the blood protein is blood meal or spray dried hemoglobin.5. The method of claim 1 , wherein the oxidizing agent is selected from the group consisting of peracetic acid claim 1 , hydrogen peroxide claim 1 , sodium chlorite claim 1 , sodium hypochlorite ...

DENSE FIBRILLAR COLLAGEN MATRICES FOR TISSUE REPAIR AND THE PREPARATION METHOD THEREOF

Method for preparing a homogeneous collagen-based material by concentration of a collagen solution, includes bringing a collagen solution into contact by way of continuous injection and use of the material for tissue repair. 1. Method for preparing a homogeneous collagen-based material by concentration of a collagen solution , said method comprising:a) bringing into contact, by continuous injection of a collagen solution by controlled pressure means with a permeable element, said permeable element itself being in contact with a concentrating agent such as a polymer solutionb) keeping the collagen solution, permeable element and polymer solution in contact under conditions allowing the selective mass transfer of the solvent contained in the aqueous collagen solution in order to obtain the formation of the homogeneous collagen material inside the permeable element or on the surface of the permeable element.2. Method for preparing a homogeneous collagen-based material according to characterized in that the permeable element is a dialysis cell claim 1 , said method comprising the following stages:a) preparation of an acid solution of pure collagen in an aqueous solvent,b) continuous injection of the pure collagen solution by controlled pressure means, into dialysis cells at least one of the ends of which is closed by a dialysis membrane the porosity of which is fixed so that only the solvent as well as the acid and the ions, if they are present, diffuse through said membrane, said membrane being in contact with a polymer solution, the concentration of which is adapted to the final collagen concentration,c) keeping the collagen solution, dialysis cell and polymer under conditions allowing the selective mass transfer of the solvent contained in the aqueous collagen solution in order to obtain the formation of the pure homogeneous concentrated collagen solution in the dialysis cell or on the surface of the dialysis membrane,d) recovery of the mould in which the material is ...

Isolation and deglycosylation of glycoproteins

The invention provides more rapid and cost-effective methods of deglycosylating target glycoproteins. In methods of the invention, the target glycoprotein is isolated from initial samples, which may contain multiple other glycoproteins, by subjecting the initial sample to a solid phase containing an affinity ligand, such as a deglycosylated antibody, that interacts specifically with the target glycoprotein. Once separated from the sample, the target glycoprotein can be deglycosylated in situ, or eluted from the solid phase, quantitated, and then deglycosylated.

CONVERSION OF CORN GLUTEN MEAL INTO A SOLID ARTICLE THROUGH THE USE OF A NON-TOXIC ADDITIVE

Disclosed are fast-curing, inexpensive corn-gluten resin compositions, methods for making them, methods for forming them into solid articles. In some embodiments, the resin composition includes corn meal gluten and a non-toxic organic acid. 1. A resin composition for molding formed articles comprising: about 70% to about 99% w/w corn meal gluten,', 'about 1% to about 18% organic acid, and', 'an optional solvent., 'a resin component itself comprising by weight of the resin component2. The resin composition of further comprising a reinforcement/filler component claim 1 , the reinforcement/filler component comprising up to about 40% by weight of the resin composition.3. The composition of claim 1 , wherein the organic acid is selected from lactic acid claim 1 , citric acid claim 1 , sorbic acid claim 1 , malic acid claim 1 , succinic acid claim 1 , and maleic acid.4. The resin composition of claim 1 , comprising at least about 98% corn meal gluten by weight of the resin component.5. The resin composition of claim 1 , comprising at least about 97% corn meal gluten by weight of the resin component.6. The resin composition of claim 1 , comprising at least about 92.5% corn meal gluten by weight of the resin component.7. The resin composition of claim 1 , comprising at least about 90% corn meal gluten by weight of the resin component.8. The resin composition of claim 1 , comprising at least about 87.5% corn meal gluten by weight of the resin component.9. The composition of claim 1 , wherein said reinforcement/filler component is selected from natural fibers claim 1 , sawdust claim 1 , inorganic fibers claim 1 , inorganic particles claim 1 , foaming agents claim 1 , clays claim 1 , zeolites claim 1 , and combinations thereof.10. A formed article comprising: about 70% to about 99% w/w corn meal gluten,', 'about 1% to about 18% organic acid, and', 'an optional solvent., 'a resin component itself comprising by weight of the resin component, 'a resin composition11. The formed ...

METHODS FOR PREPARING PEG-HEMOGLOBIN CONJUGATES USING REDUCED REACTANT RATIOS

The present invention relates generally to methods for preparing polyethylene glycol (“PEG”) conjugated hemoglobin (“Hb”) using reduced reactant ratios. More specifically, the present invention relates to methods for preparing PEG conjugated Hb (“PEG-Hb”) with enhanced yield and purity. 1. A method for preparing polyethylene glycol conjugated hemoglobin (PEG-Hb) comprising the steps of:a) mixing hemoglobin (Hb) with 2-iminothiolane (2-IT) in an aqueous diluent, wherein the 2-IT is at a concentration of between 7 and 8 molar excess in the diluent over the Hb concentration, to form thiolated Hb; andb) adding polyethylene glycol (PEG)-maleimide (Mal) to the thiolated Hb in the aqueous diluent, wherein the PEG-Mal is at a concentration of between 9 and 15 molar excess in the diluent over the Hb concentration to form a PEG-Hb conjugate, wherein the PEG-Mal has an average molecular weight of between 4,000 and 6,000 daltons (Da);wherein the PEG-Hb conjugate contains an average of between 7.1 and 8.9 PEG molecules per Hb; andwherein the PEG-Hb conjugate has a tighter molecular weight distribution than a PEG-Hb conjugate prepared using a higher molar ratio of 2-IT or PEG-Mal.2. The method according to claim 1 , wherein the 2-IT is at a concentration of 7.5 molar excess in the diluent over the Hb concentration.3. The method according to claim 1 , wherein the PEG-Mal is at a concentration of 12 molar excess in the diluent over the Hb concentration.4. The method according to claim 1 , wherein the PEG-Mal has an average molecular weight of 5 claim 1 ,000 Da.5. The method according to claim 1 , wherein the PEG-Hb conjugate has a partial pressure of oxygen at which the Hb is 50% saturated (p50) less than native stroma free hemoglobin from an equivalent source when measured under essentially identical conditions.6. The method according to claim 5 , wherein the p50 of the PEG-Hb conjugate is less than 10 millimeters of mercury (mmHg).7. The method according to claim 5 , wherein the ...

Thermo-responsive polymer covalently bound with a peptide

A thermo-responsive polymer covalently bound with a peptide, wherein the peptide comprises a peptide moiety that is able to self-assemble and a functional peptide moiety comprising a bioactive sequence, and compositions comprising such thermo-responsive polymer covalently bound with a peptide. Methods for the preparation of such thermo-responsive polymers covalently bound with a peptide and the use thereof for the preparation of hydrogels. 1. A thermo-responsive polymer covalently bound with at least one peptide , wherein the peptide comprises a peptide moiety that is able to self-assemble and a functional peptide moiety comprising a bioactive sequence.2. The polymer according to claim 1 , wherein the bioactive sequence of the functional peptide moiety is a cell adhesion providing amino acid sequence.3. The polymer according to claim 1 , wherein the at least one peptide is covalently bound with the thermo-responsive polymer through a linkage selected from the group consisting of thioether linkage claim 1 , amino linkage claim 1 , amido linkage claim 1 , ester linkage claim 1 , and ether linkage.5. The polymer according to claim 1 , wherein said peptide moiety that is able to self-assemble is self-assembling in a β-sheet claim 1 , a coiled coil a-helix structure claim 1 , a peptide triple helix structure claim 1 , or combinations thereof.6. The polymer according to claim 1 , wherein said peptide moiety that is able to self-assemble into a β-sheet claim 1 , and wherein said peptide moiety is an octapeptide moiety comprising alternating hydrophobic and charged amino acids.7. The polymer according to claim 19 , wherein the peptide moiety that is able to self-assemble into a β-sheet is selected from the group consisting of FEFKFEFK claim 19 , FEFEFKFK claim 19 , FDFKFDFK claim 19 , FDFDFKFK claim 19 , FEFRFEFR claim 19 , FEFEFRFR claim 19 , YDYKYDYK claim 19 , YDYDYKYK claim 19 , YEYRYEYR claim 19 , YEYKYEYK claim 19 , YEYEYKYK claim 19 , WEWKWEWK claim 19 , WEWEWKWK ...

PLASTIC MOLDING COMPOSITION AND SINTERED PRODUCT

A plastic molding composition includes a powder, gelatin, a polar solvent, and an adhesion reducer. The powder contains at least one of a ceramic particle and a metal particle. The adhesion reducer reduces adhesion of the gelatin so that a molded product, which is molded from the composition with a molding die, is removed from the molding die without being broken. The adhesion reducer is a water-soluble or water-dispersible compound. The adhesion reducer has a HLB value, calculated by Griffin's method, ranging from 10 to 20. 1. A plastic molding composition comprising:a powder containing at least one of a ceramic particle and a metal particle;gelatin;a polar solvent; andan adhesion reducer that reduces adhesion of the gelatin so that a molded product, which is molded from the composition with a molding die, is removed from the molding die without being broken, whereinthe adhesion reducer is a water-soluble or water-dispersible compound, and{'b': '20', "the adhesion reducer has a HLB value, calculated by Griffin's method, ranging from 10 to ."}2. The plastic molding composition according to claim 1 , whereinthe compound is at least one selected from the group consisting of polyalkylene glycol, polyalkylene glycol derivative, polycarboxylic acid, polycarboxylate, sugar alcohol, and sugar derivative.3. The plastic molding composition according to claim 1 , wherein a mixing ratio of the compound to the gelatin is 0.6 to 118 parts by weight of the compound to 100 parts by weight of the gelatin.4. A sintered product manufactured by molding and sintering the plastic molding composition according to .5. The plastic molding composition according to claim 2 , wherein a mixing ratio of the compound to the gelatin is 0.6 to 118 parts by weight of the compound to 100 parts by weight of the gelatin.6. A sintered product manufactured by molding and sintering the plastic molding composition according to .7. A sintered product manufactured by molding and sintering the plastic ...

PRODUCT OF CROSSLINKED MATERIAL AND METHOD FOR PRODUCING THE SAME

A method for producing a nanofiber-based product includes providing a carrier material solution having a carrier material, and bringing the carrier material in contact with a collector by electrospinning. The carrier material essentially consists of a polymer being—at least after having contacted the collector—embedded in a polymer, which polymer is formed by a crosslinker of the general formula (I) 3. The Method according to claim 1 , wherein at least two hydroxy groups or at least two sulfhydryl groups or at least one hydroxy group and one sulfhydryl group of the compound according to general formula (I) are bound to the benzene rings of this compound.4. The method according to claim 1 , wherein the crosslinker is nordihydroguaiaretic acid.5. The method according to claim 1 , wherein the crosslinker is used in an amount of 2 to 20 percent by mass with respect to the dry mass of the polymer of the carrier material.6. The method according to claim 1 , wherein the carrier material is crosslinked before it reaches the collector.7. The method according to claim 1 , wherein the carrier material comprises one or more of collagen claim 1 , a mixture of collagen and hydroxy apatite claim 1 , gelatin claim 1 , alginates claim 1 , chitosan claim 1 , silk claim 1 , cellulose claim 1 , polyurethane claim 1 , a polyester claim 1 , polycaprolactone claim 1 , polylactide claim 1 , polypyrrole claim 1 , polyaniline claim 1 , polyacetylene claim 1 , polythiophene claim 1 , a copolymer of the preceding polymers claim 1 , a copolymer bearing carboxylic acid groups and/or amine groups claim 1 , oligopeptides and polypeptides.8. The method according to claim 1 , wherein the electrospinning is done at a voltage of 8 to 20 kV between the collector and the spinning device.9. The method according to claim 1 , wherein the polymer is solved or dispersed in at least one liquid chosen from the group of water claim 1 , alcohols like methanol or ethanol claim 1 , aqueous solutions of acids or ...

HIGH DENSITY MEMBRANE PROTEIN MEMBRANES

Embodiments of the invention provide methods for preparing high density membrane protein membranes by slow, controlled removal of detergent from mixtures of detergent, block copolymers and membrane protein mixtures. Membranes created by this method are also provided. The structure of these membranes may be varied by varying the amount of membrane protein. 1. A method for preparing a block copolymer/protein membrane , comprising:preparing a mixture comprising at least one block copolymer, at least one detergent, and at least one protein, wherein said block copolymer is solubilized in the detergent;removing the detergent at a slow, controlled rate from said mixture until the concentration of detergent is below the mixture's critical micelle concentration;optionally removing additional detergent, either in the same or a different way that detergent was removed at a slow, controlled rate from the mixture; andforming a membrane comprising the block copolymer and the membrane protein at high density representing a molar polymer to protein ratio of 0.2-20.2. The method of claim 1 , wherein the mixture has a polymer to protein molar ratio of between 0.2 and 100.3. The method of claim 1 , wherein the detergent concentration is at least 5% wt/volume.4. The method of claim 2 , wherein the polymer to protein molar ratio is between 0.2 and 40.5. The method of claim 1 , wherein said the block copolymer is an amphiphilic diblock or triblock block copolymer comprising one or more hydrophobic blocks selected from the group consisting of polybutadiene (PB) claim 1 , polydimethylsiloxane (PDMS) claim 1 , polypropylene (PP) claim 1 , polypropylene oxide (PPO) claim 1 , polyethylethylene (PEE) claim 1 , polyisobutylene (PIB) claim 1 , polyisoprene (PI) claim 1 , polycaprolactone (PCL) claim 1 , polystyrene (PS) claim 1 , fluorinated polymers claim 1 , and polymethylmethacrylate (PMMA); and one or more hydrophilic blocks selected from the group consisting of polymethyloxazoline (PMOXA) ...

Silk Protein Composite Coating Solution and its Preparation Method and Application

Silk protein composite coating solution and its preparation method and application. In weight percent, silk protein complex coating liquid is constituted by the following substances: 2 to 10% of the crosslinking agent, 0.5 to 2% acetic acid, 10 to 20% of the silk protein, the remainder being water. The method for preparation of silk protein composite coating solution has these steps: (1) preparation of the silk protein; (2) silk protein composite coating solution was prepared. Silk protein of the present invention has a natural emollient, antibacterial, and anti-allergic effects, and can be used on daily sanitary supplies for women, infants, and elderlies.

MEDICAL DEVICE FOR BREAST SURGERY

A device is initially rolled up can unfold into its original spherical dome shape after insertion through a surgical incision. 1. A medical device for breast surgery said medical device originally constituted by a quadratic matrix of hemispherical or paraboloid or ellipsoid or hyperboloid shape , said quadratic matrix having a three-dimensional development , said matrix being rolled to obtain a solid of revolution said solid of revolution having a central section greater than the distal sections and said solid of revolution being tapered at the extremities.2. Medical device according to wherein it is equipped with a restraint device.3. Medical device according to claim 1 , wherein the quadratic matrix is made of collagen membrane having shape memory.4. Medical device according to claim 1 , wherein the restraint device is in biomaterial.5. Medical device according to claim 1 , wherein once inserted in a surgical wound the solid of revolution returns at the original hemispherical or paraboloid or ellipsoid or hyperboloid shape.6. Medical device according to claim 2 , wherein the quadratic matrix is made of collagen membrane having shape memory.7. Medical device according to claim 2 , wherein the restraint device is in biomaterial.8. Medical device according to claim 3 , wherein the restraint device is in biomaterial.9. Medical device according to claim 6 , wherein the restraint device is in biomaterial.10. Medical device according to claim 2 , wherein once inserted in a surgical wound the solid of revolution returns at the original hemispherical or paraboloid or ellipsoid or hyperboloid shape.11. Medical device according to claim 3 , wherein once inserted in a surgical wound the solid of revolution returns at the original hemispherical or paraboloid or ellipsoid or hyperboloid shape.12. Medical device according to claim 4 , wherein once inserted in a surgical wound the solid of revolution returns at the original hemispherical or paraboloid or ellipsoid or hyperboloid ...

COLLAGEN SCAFFOLD FOR CELL GROWTH AND A METHOD FOR PRODUCING SAME

A bioscaffold and method of manufacture is described. The bioscaffold has greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. A method of manufacture incorporates the steps of: (a) isolating collagen fibers or bundles; (b) incubating the fibers or bundles in a mixture of NaOH, alcohol, acetone, HCl and ascorbic acide; and (c) mechanical manipulation of the fibers or bundles to produce knitted structure. 1. A bioscaffold comprising greater than 80% type I collagen fibers or bundles having a knitted structure and a maximum tensile load strength of greater than 20N. This instant application is a continuation of, and claims priority to U.S. patent application Ser. No. 13/055,234 filed Apr. 20, 2011, which is a national stage application of International Application No. PCT/AU2009/000946, filed Jul. 24, 2009, which claims the benefit of Australian Application No. 2008903789, filed Jul. 24, 2008, the disclosures of which are incorporated herein by reference in their entirety.The present invention relates to bioscaffolds and methods of manufacturing bioscaffolds. In particular the invention relates to a bioscaffold comprising greater than 80% type I collagen fibers or bundles having a knitted structure providing mechanical strength and elasticity.Bioscaffolds are structures that replace an organ or tissue temporarily or permanently to aid the restoration of normal function. The bioscaffold provides a substrate on which cells proliferate and differentiate, eventually replacing the bioscaffold and restoring normal organ or tissue function.There are a number of properties that are desirable in a bioscaffold, these are: a) interconnecting pores that favour tissue integration and vascularisation; b) appropriately biodegrade and bioresorb such that de novo tissue ultimately replaces the scaffold; c) surface chemistry that promotes cell attachment, proliferation and differentiation; d) adequate mechanical properties; e) ...

SEPARATORS, BATTERIES, SYSTEMS, AND METHODS FOR IDLE START STOP VEHICLES

In accordance with at least selected embodiments or aspects, the present invention is directed to improved, unique, and/or high performance ISS lead acid battery separators, such as improved ISS flooded lead acid battery separators, ISS batteries including such separators, methods of production, and/or methods of use. The preferred ISS separator may include negative cross ribs and/or PIMS minerals. In accordance with more particular embodiments or examples, a PIMS mineral (preferably fish meal, a bio-mineral) is provided as at least a partial substitution for the silica filler component in a silica filled lead acid battery separator (preferably a polyethylene/silica separator formulation). In accordance with at least selected embodiments, the present invention is directed to new or improved batteries, separators, components, and/or compositions having heavy metal removal capabilities and/or methods of manufacture and/or methods of use thereof. 1. A lead acid battery separator comprising:a microporous membrane including polymer, oil, and a filler, and at least two of the following: features that help minimize acid stratification, that occupies approximately 15% less volume than traditional separators, has negative cross ribs, has a multitude of small mini-ribs in the horizontal direction, has a mechanical barrier that will hinder an acid gradient from developing, has hundreds of mini dams to keep heavier acid from flowing downward, has hundreds of mini dams which create hundreds of mini pools of acid uniformly across the surface of the electrode, and that improves power delivery and reduces acid stratification in micro-hybrid batteries.2. The battery separator according to claim 1 , wherein the filler comprises silica claim 1 , phosphate induced metal stabilization mineral claim 1 , apatite claim 1 , ground fish meal claim 1 , fish bone powder claim 1 , zeolite claim 1 , or a mixture thereof.3. The battery separator according to claim 2 , wherein the phosphate ...

POLAND SYNDROME AND METHODS OF TREATMENT

This invention is directed to grafts and compositions and methods of using the same to treat Poland Syndrome. 1. A composition consisting essentially of decellularized dermis and/or decellularized epidermis , wherein the dermis and/or epidermis retain(s) at least one matrix molecule selected from the group consisting of laminin , elastin , fibronectin , and collagen; and wherein the decellularized dermis and/or decellularized epidermis further comprises an exogenous seeded cell.2. The composition of claim 1 , wherein the dermis and/or epidermis comprises a decellularized nipple claim 1 , a decellularized areola claim 1 , or a decellularized nipple attached to a decellularized areola.3. The composition of claim 1 , wherein the exogenous seeded cell comprises a keratinocyte claim 1 , a melanocyte claim 1 , a nerve cell claim 1 , or a combination thereof.4. The composition of claim 1 , wherein the collagen comprises a Type I collagen claim 1 , a Type III collagen claim 1 , a Type IV collagen claim 1 , a Type VI collagen claim 1 , or a combination thereof.5. The composition of further comprising a cross-linking agent.6. The composition of claim 5 , wherein the cross-linking agent comprises glutaraldehyde claim 5 , genipin claim 5 , or a combination thereof7. An implantable surgical graft comprising the composition of any one of -.14. The method of claim 5 , claim 5 , claim 5 , claim 5 , claim 5 , or claim 5 , wherein the exogenous seeded cell comprises a keratinocyte claim 5 , a melanocyte claim 5 , a nerve cell claim 5 , or a combination thereof.15. The method of claim 14 , wherein the seeded nerve cell comprises seeded neurospheres or seeded neuronal cells.16. The method of claim 14 , claim 14 , claim 14 , claim 14 , claim 14 , or claim 14 , wherein the collagen comprises a Type I collagen claim 14 , a Type III collagen claim 14 , a Type IV collagen claim 14 , a Type VI collagen claim 14 , or a combination thereof. This application claims priority from U.S. ...

MULTIFUNCTIONAL BIOCOMPOSITE ADDITIVE COMPOSITIONS AND METHODS

Biocomposite compositions and compositions, which include dried distillers solubles, and which can be used in making biocomposite compositions are described. Methods for preparing the compositions are also described. 1. An extruded biopolymer composition comprising:0.01 wt % to about 95 wt % of thermoplastic material and combinations thereof; anddried distillers solubles in an amount effective to reduce an extrusion processing temperature relative to an extruded biopolymer composition without the dried distillers solubles.2. The extruded biopolymer composition of claim 1 , wherein the extrusion processing temperature is about 10 to about 35% less relative to an extrusion processing temperature of an extruded biopolymer composition without the dried distillers solubles.3. The extruded biopolymer composition of claim 1 , wherein the dried distillers solubles is at about 0.15 weight percent to about 10 weight percent of the extruded biopolymer composition.4. The extruded biopolymer composition of claim 1 , further comprising a latex compound.5. The extruded biopolymer composition of claim 1 , wherein the thermoplastic material is a mixture of different thermoplastic materials.6. The extruded biopolymer composition of claim 1 , wherein the thermoplastic material is a mixture of different thermoplastic materials that are not compatible when extruded without the dried distillers solubles claim 1 , and wherein the extrusion processing temperature is effective to form a homogenous mixture after extrusion.7. The extruded biopolymer composition of claim 1 , wherein the thermoplastic material comprises recycled plastics.8. The extruded biopolymer composition of claim 1 , wherein the thermoplastic material is selected from the group consisting of polyamides claim 1 , polyolefins claim 1 , polyvinyl chloride claim 1 , polyacrylate claim 1 , polyacetate claim 1 , polystyrene claim 1 , styrene-acrylonitrile copolymer claim 1 , and mixtures thereof.9. The extruded biopolymer ...

Adhesive compositions made from plant protein and phenolics

The present disclosure relates to adhesive compositions made from the reaction product of plant protein and phenolics, and method of making and using the adhesive compositions. A maximum bonding strength of 7.8±1.5 MPa was obtained using only 1 weight % tannic acid in a zein matrix of pH=7 and cured at 120° C.

SYNTHETIC, MUCUS-LIKE HYDROGEL AND METHOD OF PREPARATION, AND SYSTEM AND METHOD FOR PERFORMING MICRORHEOLOGY ON HYDROGELS AND OTHER COMPLEX FLUIDS

A synthetic hydrogel is described, including hydrated mucin glycoproteins cross-linked with multi-arm thiol functional cross-linker, which can be prepared to model viscoelastic and micro-rheological properties of natural mucus. Such synthetic hydrogel can be prepared from a wide variety of mucin raw materials. Also described is a method of microrheologically characterizing mucus, by dispersing in the mucus muco-inert particles (MIP), irradiating the mucus containing MIP with polarized light, and measuring fluorescence polarization (FP) resulting from rotational diffusion of the MIP in the mucus in response to such irradiating, as a microrheological characteristic of the mucus. This method can be carried out using a plate reader equipped with a spectrofluorometer and polarized filter set, and therefore can be readily carried out in clinical settings without the necessity of specialized microrheological equipment. 1. A synthetic hydrogel , comprising hydrated mucin glycoproteins cross-linked with multi-aim thiol functional cross-linker.2. The synthetic hydrogel of claim 1 , wherein the multi-arm thiol functional cross-linker comprises thiol functionality at the termini of multiple ones of its arms.3. The synthetic hydrogel of claim 1 , wherein the multi-arm thiol functional cross-linker has four arms claim 1 , each of which is linked at a central organic core structure and extends outwardly therefrom claim 1 , and comprises polyalkyloxy linear segments and a terminal thiol functionality.4. The synthetic hydrogel of claim 1 , wherein each arm of the multi-armor thiol functional cross-linker comprises a chain structure of the formula —O(CHCHO)CHCHSH wherein n is in a range of from 1 to 1000.5. The synthetic hydrogel of claim 1 , wherein the mucin glycoproteins are porcine mucin glycoproteins claim 1 , bovine mucin glycoproteins claim 1 , or human mucin glycoproteins.7. The synthetic hydrogel of claim 6 , wherein the mucin glycoproteins are porcine mucin glycoproteins or ...

METHOD FOR PREPARING BIOLOGICAL TISSUE

A method for preparing tissue for medical applications, in particular tissue for use for an artificial heart valve, wherein the method has the steps of decellularizing the tissue by means of a detergent and subsequently cross-linking the collagen fibers of the tissue by means of a suitable cross-linking agent. At least one lipopeptide, such as surfactin, for example, is used as the detergent for decellularization. 1. A method for preparing tissue for medical applications , in particular tissue for use for an artificial heart valve , comprising:decellularizing the tissue by means of a detergent, and subsequentlycross-linking the collagen fibers of the tissue by means of a suitable cross-linking agent;characterized in thatthe detergent for decellularization contains at least one lipopeptide having amphiphilic properties, comprising a hydrophilic base structure and a hydrophobic side chain.2. The method according to claim 1 , characterized in that the detergent for decellularization contains a cyclic lipopeptide claim 1 , in particular surfactin.3. The method according to claim 1 , characterized in that the detergent contains surfactin claim 1 , daptomycin claim 1 , caspofungin claim 1 , arthrofactin claim 1 , an echinocandin claim 1 , an iturin claim 1 , a syringomycin claim 1 , a syringopeptide claim 1 , and/or a polymyxin.4. The method according to claim 1 , characterized in that the cross-linking agent contains glutaraldehyde claim 1 , carbodiimide claim 1 , formaldehyde claim 1 , glutaraldehyde acetals claim 1 , acyl azides claim 1 , cyanimide claim 1 , genipin claim 1 , tannin claim 1 , pentagalloyl glucose claim 1 , phytate claim 1 , proanthocyanidin claim 1 , reuterin and/or epoxide compounds.5. The method according to claim 1 , characterized in that the tissue is rinsed before and/or after decellularization at least once with a suitable solvent claim 1 , in particular a buffered saline solution and/or an alcohol solution.6. The method according to claim 1 , ...

PROGRAMMING PROTEIN POLYMERIZATION WITH DNA

The present disclosure is generally directed to methods for making protein polymers. The methods comprise utilizing oligonucleotides for controlling the association pathway of oligonucleotide-functionalized proteins into oligomeric/polymeric materials. 1. A method of making a protein polymer comprising contacting:(a) a first protein monomer comprising a first protein to which a first oligonucleotide is attached, the first oligonucleotide comprising a first domain (V) and a second domain (W); and(b) a second protein monomer comprising a second protein to which a second oligonucleotide is attached, the second oligonucleotide comprising a first domain (V′) and a second domain (W′),wherein (i) V is sufficiently complementary to V′ to hybridize under appropriate conditions and (ii) W is sufficiently complementary to W′ to hybridize under appropriate conditions, and wherein the contacting results in V hybridizing to V′,thereby making the protein polymer.2. The method of claim 1 , wherein the contacting allows W to hybridize to W′.3. The method of or claim 1 , wherein the first protein and the second protein are the same.4. The method of or claim 1 , wherein the first protein and the second protein are different.5. The method of any one of - claim 1 , wherein the first protein and the second protein are subunits of a multimeric protein.6. The method of any one of - claim 1 , wherein the first oligonucleotide is attached to the first protein via a lysine or cysteine on the surface of the first protein.7. The method of any one of - claim 1 , wherein the first oligonucleotide is DNA claim 1 , RNA claim 1 , a combination thereof claim 1 , or a modified form thereof.8. The method of any one of - claim 1 , wherein V is from about 10-100 nucleotides in length.9. The method of any one of - claim 1 , wherein W is from about 10-100 nucleotides in length.10. The method of any one of - claim 1 , wherein the second oligonucleotide is attached to the second protein via a lysine or ...

CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. 1. A cell sheet construct for neurovascular reconstruction , comprising:a vascular endothelial cell layer having vascular endothelial cells; anda neural stem cell layer having neural stem cells;wherein the vascular endothelial cell layer is physically in direct contact with the neural stem cell layer, the vascular endothelial cell layer differentiates into branching vasculatures, and the neural stem cell layer differentiates into neurons.2. The cell sheet construct of claim 1 , wherein the vascular endothelial cells are human cerebral microvascular endothelial cells.3. The cell sheet construct of claim 1 , wherein the neural stem cells are human cerebral neural stem cells.4. The cell sheet construct of claim 1 , wherein the vascular endothelial cell layer further comprises extracellular matrix claim 1 , and the extracellular matrix as well as the vascular endothelial cells are used as a carrier.5. The cell sheet construct of claim 4 , wherein the extracellular matrix comprises polypeptide claim 4 , collagen claim 4 , polysaccharide claim 4 , hyaluronic acid claim 4 , ...

Methods and Compositions for Maintaining the Conformation and Structural Integrity of Biomolecules

A liquid ink composition includes a liquid phase and particles suspended in the liquid phase, the particles containing a target pharmaceutical or biological agent. The biological activity of the target pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase. The liquid phase is capable of solidifying via a solidification process. 1. A liquid ink composition comprising:a liquid phase andparticles suspended in the liquid phase, the particles containing a pharmaceutical or biological agent,wherein the biological activity of the pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase,wherein the liquid phase is capable of solidifying to form three dimensional structures.2. The liquid ink composition of claim 1 , the particles being formed by a process comprising: a pharmaceutical or a biological agent; and', 'a substrate that is soluble in the solution, comprising one or more chemical species;, 'preparing a solution, formed from water as a solvent, comprisingcombining the solution with an oil phase to form a water-in-oil emulsion in which the solution is dispersed in the oil phase;lyophilizing the emulsion,wherein the particles are formed prior to or simultaneously with the lyophilizing,wherein the pharmaceutical or biological agent is entrapped by the formed particles,wherein the substrate composition and the oil phase are selected so that the particles formed are suspendable in the liquid ink composition and the biological activity of the pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid ink composition, andwherein one or more substances selected from the group consisting of a surfactant, a stabilizer, an emulsifier, and combinations thereof are incorporated as part of the substrate.3. The liquid ink composition of claim 1 , wherein the biological activity of the pharmaceutical or biological agent is preserved upon solidification of ...

COMPOSITIONS AND METHODS FOR REPAIRING CARTILAGE DEFECTS

The present disclosure provides compositions and methods for repairing cartilage defects. 1. A composition comprising:cultured allogeneic cells grown from a cryogenically frozen cell bank sample; anda resorbable collagen membrane;{'sup': '2', 'wherein the cells are seeded on the membrane at a density of at least 250,000 cells per cm.'}2. A method of manufacturing an allogeneic cartilage matrix , the method comprising steps of:thawing a cryogenically frozen cell bank sample;culturing the cells of the sample;characterizing the sample;preparing a resorbable collagen membrane;seeding the membrane with the culture; andpackaging the membrane.3. A composition for use in therapy , wherein the composition comprises:cultured allogeneic cells grown from a cryogenically frozen cell bank sample; anda resorbable collagen membrane;{'sup': '2', 'wherein the cells are seeded on the membrane at a density of at least 250,000 cells per cm.'}4. A composition for use in a method of treating a chondral and/or osteochondral defect , wherein the composition comprisescultured allogeneic cells grown from a cryogenically frozen cell bank sample; anda resorbable collagen membrane;{'sup': '2', 'wherein the cells are seeded on the membrane at a density of at least 250,000 cells per cm.'}5. A cell bank for use in a method of manufacturing a matrix , wherein the matrix comprises:cultured allogeneic cells grown from a cryogenically frozen cell bank sample; anda resorbable collage membrane;{'sup': '2', 'wherein the cells are seeded on the membrane at a density of at least 250,000 cells per cm.'}6. A composition for use in a method of treating a chondral defect and/or osteochondral defect ,wherein the method comprises implanting a composition comprising cultured allogeneic cells.7. The method or composition of any one of - , wherein the cryogenic cell bank sample is thawed in a water bath , a heat block , or a dry cell bath at about 37° C.8. The method or composition of any one of - , wherein the ...

Shaped corneal segments: corneal allogenic intra-stromal devices (ring segments and rings, modified discs, modifications) for inducing shape change, regularization and stabilization of cornea in corneal ectasia and other corneal conditioins and for correction of refractive errors

A device for implantation into the cornea intra-stromally comprising allogenic comeal or scleral material or other bioengineered material including, but not limited to, processed collagen tissues, comprises a segment that is inserted into a comeal channel whereby the segment regularizes the conical cornea, gives an improved surface, improves biomechanical strength distribution and stability improves optical functionality, and improves/corrects the refractive error or gives other desired shape change effects.

Keratoprosthesis

The invention comprises a method of making molded, double-crosslinked (i.e., two stages of crosslinking), transparent, collagen materials using a novel combination of diafiltration, lyophilization, and homogenization. The collagen material can be used not only as an ophthalmic device, but also as a tissue scaffold, drug delivery device, wound dressing, or other collagen hydrogel based device.

Stem Cell Seeded Natural Substrates and Methods Relating Thereto

This disclosure provides compositions for treating tissue injuries comprising a tissue-derived substrate and mesenchymal stem cells adhered thereto, as well as methods of making and using such compositions. The tissue-derived substrates include bone, cartilage, and collagen matrix. 1. A method of making an allograft composition for treating a soft tissue injury , the method comprising:(a) providing a cell suspension comprising mesenchymal stem cells and non-mesenchymal stem cells derived from tissue obtained from a cadaveric donor;(b) seeding the cell suspension onto an acellular collagen matrix derived from tissue obtained from the cadaveric donor;(c) incubating the acellular collagen matrix seeded with the cell suspension under conditions suitable for adhering the mesenchymal stem cells to the acellular collagen matrix to form a seeded matrix; and(d) rinsing the seeded matrix to remove the non-adherent cells from the seeded matrix, thereby forming the allograft composition comprising the acellular collagen matrix with mesenchymal stem cells adhered thereto.2. The method of claim 1 , wherein the acellular collagen matrix is skin claim 1 , dermis claim 1 , tendon claim 1 , ligament claim 1 , muscle claim 1 , amnion claim 1 , meniscus claim 1 , small intestine submucosa claim 1 , or bladder.3. The method of claim 1 , furthering comprising treating the collagen matrix to reduce immunogenicity prior to seeding the cell suspension.4. The method of claim 3 , wherein treating the collagen matrix to reduce immunogenicity comprises contacting the collagen matrix with a decellularizing agent.5. The method of claim 3 , wherein treating the collagen matrix to reduce immunogenicity comprises removing an epidermis layer without decellularizing the collagen matrix.6. The method of claim 3 , wherein the treated collagen matrix has at least 50% fewer endogenous cells than a corresponding untreated collaged matrix of the same type.7. The method of claim 3 , wherein the treated ...

Green technology for crosslinking protein molecules for various uses

The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. A hydrogel that comprises molecular pores, the hydrogel comprising: one or more crosslinked polymers formed about a plurality of pre-formed molecular crystals, wherein the crystals are formed while the polymer is in an uncrosslinked form and the molecular crystals form a porous structure within the polymers during the crosslinking of the polymers. This application is a continuation of U.S. patent application Ser. No. 15/890,719, filed Feb. 7, 2018, which is a continuation of U.S. patent application Ser. No. 15/135,978, filed Apr. 22, 2016, now U.S. Pat. No. 9,896,561, issued Feb. 20, 2018, which is a continuation of U.S. patent application Ser. No. 14/277,170, filed May 14, 2014, now U.S. Pat. No. 9,320,827, issued Apr. 26, 2016, which is a continuation of U.S. patent application Ser. No. 13/909,707, filed Jun. 4, 2013, now U.S. Pat. No. 8,728,499, issued May 20, 2014, which is a continuation of U.S. patent application Ser. No. 12/919,667, filed Aug. 26, 2010, now U.S. Pat. No. 8,668,863, issued Mar. 11, 2014, which claims priority to Patent Cooperation Treaty Application Serial No. PCT/US2009/035257, filed Feb. 26, 2009, which claims priority to U.S. Provisional Patent Application Ser. No. 61/031,651, filed Feb. 26, 2008 and entitled “DENDRITIC MACROPOROUS HYDROGELS PREPARED BY CRYSTAL ...

FISTULA GRAFTS AND RELATED METHODS AND SYSTEMS FOR TREATING FISTULAE

Described are medical graft products, systems, and methods for treating fistulae. Certain products of the invention are configured to have portions residing in and around a primary fistula opening, e.g., one occurring in a wall of the alimentary canal. One such product includes a biocompatible graft body which is configured to block at least the primary opening. The graft body includes a capping member, which is configured to contact portions of the alimentary canal wall adjacent to the primary opening, and an elongate plug member extending from the capping member, which is configured to extend into at least a portion of the fistula. In certain embodiments, a graft body component has the capacity to expand or otherwise change form to provide a suitable capping arrangement. Such a component can include a resilient wire frame, e.g., one that is self-expandable or one that requires at least some manipulation in order to expand. 1. A medical graft device useful for treating a fistula having at least a primary opening in a bodily structure wall and a fistula tract extending from the primary opening , the medical graft device comprising:a biocompatible graft body including a capping member and an elongate plug member, the capping member configured to contact portions of the bodily structure wall adjacent to the primary opening and including a support frame supporting a deformable covering material, the elongate plug member extending from the capping member and configured to fill at least a portion of the fistula tract.2. The medical graft device of claim 1 , wherein the deformable covering material comprises a naturally derived material.3. The medical graft device of claim 1 , wherein the deformable covering material comprises a non-naturally derived material.4. The medical graft device of claim 1 , wherein the deformable covering material comprises a synthetic polymeric material.5. The medical graft device of claim 1 , wherein the deformable covering material comprises a ...

BINDER CONTAINING WHEY PROTEIN

The present invention relates to an aqueous binder composition, a method of manufacturing a product comprising said binder composition in a cured state, as well as particle or fibre products comprising the binder composition in a cured state, and a use of said binder composition. 1. A method of manufacturing a product selected from a building product , a mineral wool insulation product , a wood product , an automotive product , a paper product and a refractory product , comprising the steps of:(a) providing a collection of matter,(b) applying an aqueous binder composition to the collection of matter, the aqueous binder composition comprising, by dry weight:i) between 65 wt % and 90 wt % whey protein;ii) between 0.5 wt % and 15 wt % carbohydrate;iii) between 0.5 wt % and 15 wt % fat; andiv) between 0.5 wt % and 15 wt % ash; and(c) curing the binder applied to the collection of matter by applying energy to the collection of matter to form the product.2. The method according to claim 1 , wherein the binder holds the collection of matter together to form the product.3. The method according to claim 1 , wherein the collection of matter comprises matter selected from the group consisting of wood claim 1 , wood particles claim 1 , cellulose fibres and mineral fibres.4. The method according to claim 1 , wherein the aqueous binder composition comprises at least 95% by dry weight of whey protein preparation.5. The method according to claim 1 , wherein the aqueous binder composition comprises at least one additive selected from the group consisting of silanes claim 1 , waxes claim 1 , catalysts claim 1 , surfactants and corrosion inhibitors claim 1 , wherein the total amount of silanes claim 1 , waxes claim 1 , catalysts claim 1 , surfactants and corrosion inhibitors by dry weight in the aqueous binder composition is in the range of 0.2 wt % to 6 wt %.6. The method according to claim 1 , wherein the aqueous binder composition further comprises one or more polymerization ...

Protein hydrogel, preparation method and use thereof

The invention relates to a new protein hydrogel created on the basis of low-concentrated components: reagents A and B, the method of hydrogel preparation and its use.

BIOFUNCTIONALIZED HYDROGEL FOR CELL CULTURE

Provided are biomaterials useful for cell culture, method of preparation thereof, and use thereof. The present biomaterial comprises a crosslinked hydrogel and a peptide chemically attached to the hydrogel, wherein the peptide comprises a histidine-alanine-valine (HAV) sequence. In particular, the present biomaterial may be useful for culturing neurons, brain endothelial cells, and/or glial cells, supporting the formation of synaptically connected neural networks, and growing stem cell-derived organoids that more closely resemble human organs.

Techniques For Increasing The Acoustic Impedance Of The Cochlea's Round Window Membrane

A method for increasing the acoustic impedance of the round window membrane of the cochlea in a human patient includes surgically opening access to the round window membrane and placing a packing layer over the round window membrane. Optionally a layer of collagen graft may be obtained from the patient and placed between the round window membrane and the packing layer. Optionally the packing layer may be enclosed within the collagen graft. Optionally bone paté may be obtained from the patient and used to form at least a portion of the packing layer. Optionally a silastic buttress may be placed under compression between the packing layer and the bone of sinus tympani of the patient. 1. A method for increasing the acoustic impedance of the round window membrane of the cochlea in a human patient , the method comprising:surgically opening access to the round window membrane;placing a packing layer over the round window membrane.2. The method of claim 1 , further comprising:obtaining a collagen graft from the patient;placing the collagen graft between the round window membrane and the packing layer.3. The method of claim 1 , further comprising:obtaining bone material from the patient;forming a bone paté out of the bone material;forming the packing layer to comprise bone paté.4. The method of claim 2 , further comprising:obtaining bone material from the patient;forming a bone paté out of the bone material;forming the packing layer to comprise bone paté.5. The method of claim 1 , further comprising:placing a layer of absorbable biocompatible material over the packing layer.6. The method of claim 2 , further comprising:placing a layer of absorbable biocompatible material over the packing layer.7. The method of claim 3 , further comprising:enclosing the packing layer within the collagen graft.8. The method of claim 4 , further comprising:enclosing the packing layer within the collagen graft.9. The method of claim 5 , further comprising:enclosing the packing layer within the ...

Microcarriers, Matrices And Scaffolds For Culturing Mammalian Cells And Methods Of Manufacture

Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided. 1. A method of producing polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers , the method comprising the steps of:providing an oxidized polysaccharide or oxidized glycoprotein having aldehyde moieties;reacting the oxidized polysaccharide or oxidized glycoprotein with an amino polymer to form a polymer containing imine derivatives; andconverting the imine derivatives on the polymer to amines to form the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers, the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers having an amino functionality which will provide a cationic copolymeric material having a three-dimensional structure with cationic sites when protonated.2. The method of wherein the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers are di-block copolymers.3. The method of any one of wherein the aldehyde moieties are generated by selectively oxidizing hydroxyl groups on C2 and C3 of glucose units and the oxidation does not produce more carboxyl groups than aldehyde groups or cause cleavage of a polysaccharide chain.4. The method of further comprising the step of drying the polysaccharide-polyamine copolymers or glycoprotein-polyamine copolymers to form polysaccharide-polyamine copolymer particles or glycoprotein-polyamine copolymer particles.5. The method of ...

METHOD FOR SHAPING TISSUE MATRICES

Methods for shaping tissue matrices are provided. The methods can be used to produce shaped tissue products that retain desired biologic properties without using chemical crosslinking agents. 1. A method for shaping a tissue matrix to support a breast implant , comprising:selecting a collagen-containing tissue matrix;partially dehydrating the tissue matrix;applying mechanical forces to the tissue matrix to form a cup shape; andexposing the tissue matrix while partially dehydrated to ionizing radiation to stabilize at least a portion of the tissue matrix.2. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.3. The method of claim 1 , wherein the tissue matrix comprises a dermal tissue matrix.4. The method of claim 1 , wherein the tissue matrix is produced from a tissue selected from fascia claim 1 , pericardial tissue claim 1 , dura claim 1 , umbilical cord tissue claim 1 , placental tissue claim 1 , cardiac valve tissue claim 1 , ligament tissue claim 1 , tendon tissue claim 1 , arterial tissue claim 1 , venous tissue claim 1 , neural connective tissue claim 1 , urinary bladder tissue claim 1 , ureter tissue claim 1 , or intestinal tissue.5. The method of claim 1 , wherein partially dehydrating the tissue matrix includes removing water to produce a tissue matrix containing between 95% (w/w) and 50% (w/w) water content.6. The method of claim 5 , wherein the water content is between 80% (w/w) and 65% (w/w).7. The method of claim 5 , wherein the water content is between 85% (w/w) and 50% (w/w).8. The method of claim 5 , wherein the water content is between 80% (w/w) and 50% (w/w).9. The method of claim 5 , wherein the water content is between 90% (w/w) and 50% (w/w).10. The method of claim 5 , wherein the water content is between 90% (w/w) and 60% (w/w).11. The method of claim 5 , wherein the water content is between 90% (w/w) and 65% (w/w).12. The method of claim 1 , further comprising rehydrating the tissue matrix.13. The method of claim ...

A MEDICAL PROCEDURE KIT AND A RELATED METHOD

The present disclosure provides a medical procedure kit for ameliorating tissue damage in a patient, the kit comprising a container enclosing a receptacle, an extractor for extracting biological material including autologous cells from the patient, a strainer for straining autologous cells from the biological material and an implantable support having a surface onto which the autologous cells can adhere, the implantable support configured to be received by the receptacle. Also disclosed are related methods of manufacturing a medical material and using the medical procedure kit. 1. A medical procedure kit for ameliorating tissue damage in a patient , the kit comprising a container enclosing the following components:a receptacle;an extractor for extracting biological material including autologous cells from the patient;a strainer for straining autologous cells from the biological material; andan implantable support having a surface onto which the autologous cells can adhere, the implantable support configured to be received by the receptacle.2. The kit of claim 1 , wherein the container can be opened to access the components therein.3. The kit of claim 2 , wherein prior to opening the container a first time for use claim 2 , the container is sealed closed.4. The kit of claim 3 , wherein an internal region of the kit and the components are sterilised prior to opening the container the first time.5. The kit of claim 2 , wherein the container comprises predefined storage locations for one or more of the implantable support claim 2 , extractor and strainer.6. The kit of claim 2 , wherein the receptacle is integrated with the container.7. The kit of claim 6 , wherein the receptacle is a depression formed in a surface in an inner region of the container.8. The kit of claim 1 , wherein the extractor comprises a hollow needle and a syringe.9. The kit of claim 8 , wherein the hollow needle and syringe are provided as separate components in the container and are demountably ...

Composition for a Molded Body

The present disclosure relates to a composition for a molded body comprising a recombinant spider silk protein, and a plasticizer. Further, the present disclosure relates to a molded body comprising a recombinant spider silk protein and a plasticizer, and a process for preparing the molded body. 1. A composition for a molded body comprising a recombinant spider silk protein and a plasticizer , wherein the composition is capable of being induced into a flowable state , wherein the recombinant spider silk protein is substantially non-degraded in the flowable state.237.-. (canceled)38. A process for preparing a molded body , comprising the steps of:(a) applying pressure and shear force to a composition comprising a recombinant spider silk protein and a plasticizer to transform the composition to a flowable state, and(b) extruding the composition in the flowable state to form a molded body.39. The process of claim 38 , wherein extruding the composition to form a molded body comprises extruding the composition to form a fiber or extruding the composition into a mold.40. The process of claim 39 , wherein extruding the composition to form a fiber comprises extruding the composition through a spinneret.41. (canceled)42. The process of claim 38 , further comprising:(a) applying pressure and shear force to the molded body to transform the molded body to a composition in a flowable state, and(b) extruding the composition in the flowable state to form a second molded body.43. The process of claim 42 , further comprising repeating steps (a) and (b) to the second molded body at least once.44. The process of claim 38 , wherein said shear force is from 1.5 to 13 Nm.45. (canceled)46. The process of claim 38 , wherein the shear force and pressure are applied to the composition using a capillary rheometer or a twin screw extruder.47. The process of claim 46 , wherein the screw speed of the twin screw extruder ranges from 10 to 300 RPM during application of said pressure and shear ...

BONE PUTTY AND GEL SYSTEMS AND METHODS

A collagen-bone composition may include bone collagen and bone particles. The collagen may be in the form of a collagen suspension and the bone particles may be demineralized bone particles retained in collagen suspension. The composition may be prepared from pressure and thermal treatment of dry demineralized bone particles contacted with an aqueous medium to produce a viscous gel-like fluid. The fluid may include the collagen extracted from the demineralized bone particles. Addition of particulate bone may be used to increase the consistency of the composition, which may convert it into a paste or putty. The paste or putty may be suitable for ejection from a syringe. The collagen-bone composition may be preserved by freeze-drying or preferably by hypothermic dehydration. On reconstitution with aqueous medium, the preserved material may resume its original shape and properties. 19-. (canceled)10. A method of making a collagen-bone mixture , the method comprising:contacting dried partially demineralized microparticulate bone particles with aqueous medium to form a mixture of the bone particles contacted with the aqueous medium; andextracting bone collagen from the bone particles to form an extraction mixture of the substantially intact bone particles and bone collagen, wherein the extracting comprises exposing the bone particles contacted with the aqueous medium to an elevated temperature and high pressure treatment for less than 60 minutes sufficient to extract the bone collagen from the bone particles.11. The method of claim 10 , wherein the pressure treatment is provided by steam claim 10 , and wherein the method further comprises cooling the extraction mixture.12. The method of claim 11 , wherein the bone particles comprise bone selected from the group consisting of allogeneic bone claim 11 , xenogeneic bone claim 11 , and combinations thereof.13. The method of claim 11 , wherein the bone particles are from a single donor.14. The method of claim 11 , wherein the ...

ARTIFICIAL BIOMEMBRANE USING COCOON AND METHOD FOR MANUFACTURING SAME

Disclosed herein are a cocoon-based artificial biomembrane and a method for manufacturing the same. A cocoon the shell of which has a first thickness is divided into two or more fragments in predetermined form. The cocoon fragments may be used as artificial biomembranes. They can be relatively simply manufactured in a more cost efficient manner than conventional artificial biomembranes and have excellent cell growth potential. Also contemplated are a cocoon-based artificial biomembrane having excellent tensile strength and elongation, and a method for manufacturing the same. 1. A cocoon-based artificial biomembrane , prepared by dividing a cocoon into two or more fragments in a predetermined form , the cocoon having a shell with a first thickness.2. The cocoon-based artificial biomembrane of claim 1 , wherein each of the fragments is delaminated into a lamellar fragment with a second thickness claim 1 , the second thickness being smaller than the first thickness.3. The cocoon-based artificial biomembrane of claim 2 , wherein the lamellar fragment with a second thickness is an inner stratum of the cocoon.4. The cocoon-based artificial biomembrane of claim 2 , wherein the lamellar fragment with a second thickness is a mid stratum of the cocoon.5. The cocoon-based artificial biomembrane of claim 2 , wherein the lamellar fragment with a second thickness is an outer stratum of the cocoon.6. The cocoon-based artificial biomembrane of claim 3 , wherein the lamellar fragment is sterilized.7. The cocoon-based artificial biomembrane of claim 4 , wherein the lamellar fragment is sterilized.8. The cocoon-based artificial biomembrane of claim 5 , wherein the lamellar fragment is sterilized.9. The cocoon-based artificial biomembrane of claim 6 , wherein the lamellar fragment is packed.10. A method for manufacturing a cocoon-based artificial biomembrane claim 6 , comprising a first step of dividing a cocoon into two or more fragments in a predetermined form claim 6 , the cocoon ...

OSTEOINDUCTIVE PUTTIES AND METHODS OF MAKING AND USING SUCH PUTTIES

The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing. 120-. (canceled)21. An osteoinductive putty comprising at least three components , wherein said components comprise:i. demineralized bone matrix,ii. a carrier comprising a mixture of thermally denatured collagen fragments, andiii. a further component, wherein said further component comprises one or more osteogenic substances, osteoinductive substances, osteoconductive substances and/or medically useful substances;wherein said thermally denatured collagen fragments comprising said carrier are derived from thermal treatment of demineralized bone matrix; andwherein said mixture of thermally denatured collagen fragments has a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile, and said SDS-PAGE profile comprises a region between about 29 kDa and about 97 kDa, wherein said region is without prominent, intense, or discernable bands as compared to a Type-I collagen reference material.222. The osteoinductive putty of claim 21 , wherein said mixture of thermally denatured collagen fragments has a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile substantially the same as shown in Lane C of any of claim 21 , or D.23. The osteoinductive putty of claim 21 , wherein said thermally denatured collagen fragments are formed from heating said demineralized bone matrix at about 120° C. for about 90 min.24. The osteoinductive putty of claim 21 , wherein the putty is adapted ...

Corn protein isolate and methods of manufacturing same

Aspects of the present invention provide a corn protein isolate, comprising at least about 85 wt % corn protein on a dry basis; an “a*” color value ranging from about −0.5 and 1.5, and a “b” color value ranging from about 10 and 25; and less than about 1.5% oil on a dry basis. Further aspects include methods of making the same.

Collagen Construct and Method for Producing the Collagen Construct

There is disclosed a collagen construct comprising a plurality of elongate strips, wherein each strip contains a plurality of collagen fibres that are substantially aligned along the length of the respective strips, and the strips are braided or woven together to produce a collagen construct in the form of a rope that can be used for replacing tendons or ligaments, such as cruciate ligaments. Also disclosed is a method for making or producing the collagen construct from a collagen membrane having a plurality of collagen fibres being substantially aligned parallel to each other in a common direction. The membrane is cut along cut lines that are orientated substantially parallel to that common direction, thereby to separate elongate strips from the membrane. The strips are then braided or woven together to form the collagen construct. 127.-. (canceled)28. A ligament prosthesis comprising:a plurality of elongate strips that have been cut from a collagen membrane comprising greater than 80% type I collagen and numerous collagen fibres,wherein each elongate strip comprises a plurality of collagen fibres,wherein a majority of the collagen fibres, are aligned parallel to each other in a common direction,wherein each collagen fibre has a length,wherein each elongate strip has a length of 2 cm to 20 cm, a thickness of 50 μm to 400 μm, and a width of 50 μm to 5 mm,wherein the lengths of a majority of the plurality of collagen fibres are aligned along the length of the respective elongate strips;wherein the plurality of elongate strips are braided, plaited, woven, twisted or wound together to produce the ligament prosthesis,{'sup': '2', 'wherein the ligament prosthesis has a diameter of less than or equal to 10 mm, a cross-sectional area of about 77-80 mm, and is able to withstand a tensile load of 650 N without breaking or suffering any permanent deformation or damage.'}29. The ligament prosthesis of claim 28 , wherein at least one of the collagen fibres in each elongate ...

COLLAGEN MELANOCYTE COMPLEX, PREPARATION METHOD AND USE THEREOF

The present disclosure provides a preparation method of a collagen melanocyte complex and use of the collagen melanocyte complex. The collagen material is a scaffold material with good biocompatibility, mechanical properties, and degradation performance, which is prepared based on tissue engineering technology. The present disclosure relates to the preparation of a collagen scaffold and the construction of a collagen melanocyte complex. Melanocytes on the scaffold material have higher cell activity and better melanin secretion ability. The collagen melanocyte complex avoids the loss of cell suspension during cell transplantation and provides a good three-dimensional growth environment for cells. The collagen melanocyte complex prepared by the present disclosure can be used in patients with vitiligo or patients with pigment deficiency and epidermal damage. 1. A preparation method for a collagen melanocyte complex , comprising preparing a cross-linked collagen sponge scaffold material firstly , inoculating melanocytes on the cross-linked collagen sponge scaffold material and then culturing in vitro.2. The preparation method according to claim 1 , wherein a method for preparing the cross-linked collagen sponge scaffold material comprises the following steps: adding a collagen with appropriate size to a reaction solvent claim 1 , adding a cross-linking agent to the reaction solvent claim 1 , and magnetically stirring; after completion of the reaction claim 1 , performing washing claim 1 , freeze-drying claim 1 , and sterilizing.3. The preparation method according to claim 1 , wherein the collagen is aquatic animal collagen or mammalian collagen; the collagen has a thickness of 0.5-10 mm sponge claim 1 , which is cut into a shape not larger than a petri dish; the reaction solvent is ethanol or water phase claim 1 , preferably 90% ethanol or PBS solution with pH=5.5; the cross-linking agent is EDC and NHS claim 1 , and a molar ratio of EDC:NHS is in a range of 1:1 to 1:4; ...

CURABLE FILM-FORMING COMPOSITION COMPRISING CATALYST ASSOCIATED WITH A CARRIER

A coating composition is disclosed comprising a film-forming resin and a catalyst component. The catalyst component comprises a catalyst contained within or encapsulated by a carrier; at least some of the catalyst is capable of being released from the carrier via diffusion through the carrier and into the coating composition. Methods of controlling the rate of cure of a curable film-forming composition and increasing the pot life of the composition by adding such catalyst components are also disclosed. 1. A coating composition comprising:(a) A film-forming resin; and(b) A catalyst component comprising a catalyst associated with a carrier, wherein at least some of the catalyst is capable of being released from the carrier via diffusion through the carrier and into the coating composition, and wherein the earlier is not funned from any component of the film-forming resin (a).2. The coating composition of claim 1 , wherein the carrier comprises gelatin or polyoxymethylene urea formaldehyde.3. The coating composition of claim 1 , wherein the catalyst comprises dibutyltin dilaurate claim 1 ,4. The coating composition of claim 1 , wherein the catalyst comprises 40-90 percent by weight of the total solid content of the catalyst component (b).5. The coating composition of claim 1 , wherein diffusion of the catalyst through the carrier and into the coating composition is initiated upon admixture of the catalyst component (b) with the film-forming resin (a).6. The coating composition of claim 1 , further comprising (c) a solvent claim 1 , wherein the solvent inhibits diffusion of the catalyst through the carder and into the coating composition.7. The coating composition of claim 6 , wherein the solvent demonstrates a Hansen solubility polarity parameter of 0 to 3.5 claim 6 , and a Hansen solubility hydrogen bond parameter of 0 to 6.08. The coating composition of claim 6 , wherein diffusion of the catalyst through the carrier and into the coating composition is initiated or ...

COMPOSITIONS COMPRISING MESENCHYMAL STEM CELLS AND USES THEREOF

The present invention relates to a composition comprising a biocompatible matrix and a substantially pure mesenchymal stem cells population. The present invention also relates to its use for treating soft tissue injuries. 1. A composition comprising a biocompatible matrix and a mesenchymal stem cells population , wherein said mesenchymal stem cells population is substantially pure , and wherein said mesenchymal stem cells are undifferentiated.2. The composition according to claim 1 , wherein said mesenchymal stem cells population comprises less than 25% of fibroblasts.3. (canceled)4. The composition according to claim 1 , wherein said mesenchymal stem cells are derived from the group consisting of adipose tissue claim 1 , bone-marrow claim 1 , umbilical cord tissue claim 1 , Wharton's jelly claim 1 , amniotic fluid claim 1 , placenta claim 1 , peripheral blood claim 1 , fallopian tube claim 1 , corneal stroma claim 1 , lung claim 1 , muscle claim 1 , skin claim 1 , bone claim 1 , dental tissue and fetal liver.5. The composition according to claim 1 , wherein said mesenchymal stem cells are derived from adipose tissue claim 1 , preferably from subcutaneous adipose tissue.6. The composition according to claim 1 , wherein said biocompatible matrix is acellular.7. The composition according to claim 1 , wherein said biocompatible matrix comprises collagen.8. The composition according to claim 1 , wherein said biocompatible matrix is human claim 1 , porcine claim 1 , bovine or equine.9. The composition according to claim 1 , wherein said mesenchymal stem cells originate from the subject to be treated.10. A method for treating a soft tissue injury in a subject in need thereof comprising administering to said subject a composition comprising a biocompatible matrix and a mesenchymal stem cells population claim 1 , wherein said mesenchymal stem cells population is substantially pure claim 1 , and wherein said mesenchymal stem cells are undifferentiated.11. The method ...

COMPOSITION FOR MAINTAINING EFFICACY OF FILLER

The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin. 1. A method for maintaining a filling effect of a hyaluronic acid filler comprising parenterally administering an effective amount of collagen hydrolysate to a subject in need thereof ,wherein the collagen hydrolysate maintains the filling effect of the hyaluronic acid filler.2. A method for enhancing a hyaluronic acid comprising parenterally administering an effective amount of collagen hydrolysate to a subject in need thereof ,wherein the collagen hydrolysate enhances a hyaluronic acid.3. The method according to claim 2 , wherein the enhancing a hyaluronic acid is promoting a hyaluronic acid synthesis or inhibiting an activity of hyaluronidase.4. The method according to claim 1 , wherein the collagen hydrolysate comprises a collagen tripeptide.5. The method according to claim 4 , wherein the collagen tripeptide is contained in an amount of 10 wt % or more based on the total weight of the collagen hydrolysate.6. The method according to claim 4 , wherein the collagen tripeptide is present in an amount of 15 wt % or more based on the total weight of the collagen hydrolysate.7. The method according to claim 1 , wherein the collagen hydrolysate is administered in a form of a parenteral composition and the composition comprises 0.01-50 wt % of collagen hydrolysate based on the total weight of the composition.8. The ...

REINFORCED COLLAGEN DEVICE FOR SOFT TISSUE REPAIR

Disclosed herein are embodiments of orthopedic devices. In several embodiments, orthopedic device comprises a biocompatible covering. In several embodiments the biocompatible covering is a collagen-based material. In several embodiments, the collagen-based material is crosslinked using an epoxide-based crosslinking agent (e.g., a diepoxide, triepoxide, etc.). In several embodiments, after a precursor crosslinked collagen-based material is prepared (e.g., by subjecting it to crosslinking conditions), residual crosslinking agent in the precursor material is quenched. In several embodiments, it has been surprisingly found that, by subjecting the precursor crosslinked collagen based material to a quenching reaction (to provide the crosslinked collagen-based material), improved properties are obtained (e.g., lower toxicity lower cytotoxicity, etc.). In several embodiments, the crosslinked collagen-based material is fabricated into an orthopedic device or used to prepare an orthopedic device (e.g., implant). 2. The orthopedic implant of claim 1 , wherein the support element comprises at least one of a thread claim 1 , a suture claim 1 , a sheet claim 1 , a strip claim 1 , a fabric claim 1 , and a weave.3. The orthopedic implant of claim 1 , wherein the support element comprises a braided material.4. The orthopedic implant of claim 1 , wherein the support element comprises a mesh material.5. The orthopedic implant of claim 1 , wherein the support element comprises a polymeric surgical mesh material.7. The orthopedic implant of claim 6 , wherein the orthopedic implant is sized and configured for use in an abdominal hernia treatment procedure.8. The orthopedic implant of claim 6 , wherein the orthopedic implant is configured for tendon claim 6 , ligament claim 6 , and/or other tissue repair claim 6 , support claim 6 , reconstruction and/or other treatment of a patient's hip or spine.9. The orthopedic implant of claim 6 , wherein the orthopedic implant is configured for ...

METHOD FOR PRODUCING BONE GELATINE, AND PRODUCED BONE GELATINE

The present invention relates to a method for producing bone gelatine having an isoelectric point of less than 6, comprising the following steps: a) providing bones of vertebrates; b) mechanically crushing the bones to a particle size of less than 1 500 μm, preferably less than 500 μm, more preferably less than 300 μm; c) extracting the crushed bones using an aqueous medium at a temperature of from 100 to 140° C., preferably from 120 to 130° C., for a period of from 0.5 to 10 min, preferably 1 to 5 min, more preferably 1 to 3 min; d) separating off the aqueous gelatine solution from the crushed bones; and e) drying the aqueous gelatine solution in order to obtain the bone gelatine having an isoelectric point of less than 6, wherein the method does not comprise liming of the bones with a base, and wherein the bones provided in step a) have not undergone liming. The invention further relates to bone gelatine having an isoelectric point of less than 6, produced by this method. 2. The method according to claim 1 , wherein the method does not comprise maceration of the bones with an acid claim 1 , and wherein the bones provided in step a) have not undergone maceration.3. The method according to claim 1 , wherein the bones come from mammals.4. The method according to claim 1 , wherein the bones are cleaned before being crushed.5. The method according to claim 4 ,wherein the cleaning of the bones comprises a treatment with one or more enzymes.6. The method according to claim 1 , wherein claim 1 , before crushing claim 1 , the bones have a fat content of less than 4 weight %.7. The method according to claim 1 , wherein the mechanical crushing comprises dry grinding or wet grinding of the bones.8. The method according to claim 1 , wherein the extraction is carried out with a content of crushed bones by weight in the aqueous medium of from 0.05 to 0.5 kg/1.9. The method according to claim 1 , wherein the extraction is carried out at a pH value in the range of from 7.5 to 9.10 ...

METHOD FOR MANUFACTURING BIOINDUCTIVE PATCH

A bioinductive patch includes a patch body and a button. The patch body has an inner space. The button is disposed in the inner space of the patch body. A method for manufacturing a bioinductive patch includes step in which a patch body having an inner space is provided. The method continues with step in which a button is disposed in the inner space of the patch body. 1. A method for manufacturing a bioinductive patch , comprising:providing a patch body having an inner space; anddisposing a button in the inner space of the patch body.2. The method of claim 1 , wherein the patch body is made of decellularized bioinductive collagen or amniotic membrane.3. The method of claim 1 , wherein the patch body has an opening claim 1 , and the button is disposed in the inner space through the opening.4. The method of claim 1 , wherein the button has a top surface contacting the patch body.5. The method of claim 4 , wherein the button has a plurality of top cavities formed on the top surface.6. The method of claim 5 , wherein the top cavities are disposed with at least one growth factor.7. The method of claim 1 , wherein the button has a bottom surface contacting the patch body.8. The method of claim 7 , wherein the button has a plurality of bottom cavities formed on the bottom surface.9. The method of claim 8 , wherein the bottom cavities are disposed with at least one growth factor.10. The method of claim 7 , wherein the bottom surface comprises a level plane and two inclined planes claim 7 , and the two inclined planes are located at two sides of the level plane claim 7 , respectively.11. The method of claim 1 , wherein the button has a central portion and two side curved portions claim 1 , and the two side curved portions are connected to two sides of the central portion claim 1 , respectively.12. The method of claim 11 , wherein a center maximum thickness of the central portion is greater than or equal to a thickness of the side curved portion.13. The method of claim 11 , ...

OPTICAL CYLINDER AND METHOD OF SURFACE TREATMENT OF THE SAME

Disclosed is an optical cylinder of a corneal prosthesis comprising: a) an optical cylinder comprising a solid polymer, and b) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder. Also disclosed are methods of surface treatment of optical cylinders of corneal prostheses, and corneal prostheses thereof. 1. An optical cylinder of a corneal prosthesis comprising:a) an optical cylinder comprising a solid polymer, andb) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder.2. The optical cylinder of claim 1 , wherein the solid polymer is optically transparent.3. The optical cylinder of claim 1 , wherein the solid polymer is selected from the group consisting of poly(methyl methacrylate) (PMMA) claim 1 , polystyrene claim 1 , polycarbonate claim 1 , polythiourethane claim 1 , polyethylene terephthalate claim 1 , and polypropylene.4. The optical cylinder of claim 1 , wherein the solid polymer is poly(methyl methacrylate) (PMMA).5. The optical cylinder of claim 1 , wherein the nanoparticle covers at least 70% of the circumference of the solid polymer surface of the optical cylinder.6. The optical cylinder of claim 1 , wherein the Root Mean Square (RMS) roughness (R) value of the layer is from 150 nm to 80 nm.7. The optical cylinder of claim 1 , wherein the thickness of the layer is from 30 μm to 100 μm.8. The optical cylinder of claim 1 , wherein the nanoparticle is insoluble in organic solvent.9. The optical cylinder of claim 1 , wherein the nanoparticle is selected from the group consisting of bioceramic nanoparticle claim 1 , metal nanoparticle claim 1 , and a mixture thereof.10. The optical cylinder of claim 1 , wherein the nanoparticle is a bioceramic nanoparticle selected from the group consisting of hydroxyapatite (HAp) nanoparticle claim 1 , titanium oxide (TiO) nanoparticle claim 1 , aluminum ...

Methods for Localized Modification of Tissue Products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties. 1. A method of producing a tissue matrix to support a breast implant after breast reconstruction or breast augmentation , comprising:selecting a collagen-containing tissue matrix having an upper convex surface and a lower convex surface; andcross-linking select portions of the tissue matrix in a pattern having one or more curvilinear segments to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix.2. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.3. The method of claim 1 , wherein the tissue matrix comprises a dermal tissue matrix.4. The method of claim 1 , wherein the tissue matrix is derived from a tissue selected from fascia claim 1 , pericardial tissue claim 1 , dura claim 1 , umbilical cord tissue claim 1 , placental tissue claim 1 , cardiac valve tissue claim 1 , ligament tissue claim 1 , tendon tissue claim 1 , arterial tissue claim 1 , venous tissue claim 1 , neural connective tissue claim 1 , urinary bladder tissue claim 1 , ureter tissue claim 1 , and intestinal tissue.5. The method of claim 1 , wherein cross-linking select portions of the tissue matrix comprises applying a fluid containing a cross-linking agent to the select portions.6. The method of claim 5 , wherein applying a fluid containing a cross-linking agent to the select portions comprises:providing a solid surface having one or more channels configured to allow fluid to flow therethough;contacting the tissue matrix with the surface; andcausing the fluid containing the cross-linking agent to flow through the channels.7. The method of claim 6 , wherein the one or more channels are shaped as parallel curvilinear ...

Graft For Directed Vascular And Lymphatic Regeneration And Methods To Guide Endothelial Cell Assembly

Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided. 1. A graft comprising a collagen membrane comprised of collagen fibrils having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils.2. A graft according to claim 1 , where the graft comprises a collagen membrane having an aligned-crimped structure such that mammalian cells plated on the membrane align substantially perpendicular to the ridges and grooves of the crimp pattern and primarily along the direction of the crimped fibrils.3. A graft according to claim 1 , wherein the membrane has a transmission diffraction pattern produced by a laser source with wavelength in the visible range claim 1 , such that the pattern has at least two centrally symmetric elongated “petals”.4. A graft according to claim 3 , wherein the cells are endothelial cells and their alignment degree depends on the diameter of the collagen fibrils forming the membrane.5. A graft according to claim 1 , wherein the majority of collagen fibrils have the diameter in range from 20 nm to 60 nm and wherein the cells are endothelial cells aligned mainly along the ...

Collagen Tissue Modification

Treatment systems and methods are disclosed that may be used to strengthen cartilage. The disclosed subject matter includes description of this advantage and associated experimental results. The systems and methods employ ultrafast laser-based treatment to induce crosslinks into the collagen network of the tissue media without the addition of a chemical agent. The system and related methods may also be used for other purposes discussed herein. 1. A method of stiffening cartilage , comprising:exciting reactive oxygen species by creating a multiple-photon excitation in a cartilage, the power, photon energy, and duration of the exciting being limited to prevent heating or optical breakdown in the cartilage.2. The method of claim 1 , wherein the cartilage exhibits osteoarthritis.3. The method of claim 1 , wherein the exciting includes scanning a laser on a surface of the cartilage.4. The method of claim 3 , wherein the laser is delivered as pulses carrying nano-joule (nJ) energy.5. The method of claim 4 , wherein the laser focus is such that a volume within the cartilage is excited.6. The method of claim 4 , wherein the exciting includes scanning a laser on a surface of the cartilage.7. The method of claim 3 , wherein each portion of the surface is scanned not more than twice.8. The method of claim 3 , wherein each portion of the surface is scanned no more than once.9. A method of repairing tissues claim 3 , comprising:exciting reactive oxygen species by creating a multiple-photon excitation in tissue media including cartilage, ligaments, tendon tissue, skin, and connective tissues generally, to repair or improve damage to the tissue media that forms an interface where the tissue media is divided,wherein power, photon energy, and a duration of the exciting is limited to prevent heating or optical breakdown in the tissue media.10. The method of claim 9 , further comprising applying a collagen-containing liquid at said interface.11. The method of claim 9 , wherein said ...

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. (canceled)2. An apparatus comprising:a hydrogel film having first and second opposing ends;wherein the hydrogel film includes (a)(i) uncrosslinked hyaluronic acid, (a)(ii) crosslinked alginate, and (a)(iii) at least one of a protein and a biomineral;wherein (b)(i) the alginate is crosslinked with calcium, and (b)(ii) the alginate is crosslinked around the uncrosslinked hyaluronic acid.3. The apparatus of wherein the hydrogel film includes the biomineral.4. The apparatus of wherein the hydrogel film includes the protein.5. The apparatus of wherein the protein includes a cell adhesive protein.6. The apparatus of wherein the hydrogel film includes a drug.7. The apparatus of included in a kit claim 4 , the kit comprising a calcium chelator.8. The apparatus of claim 4 , wherein the hydrogel film consists essentially of the uncrosslinked hyaluronic acid and the crosslinked alginate.9. The apparatus of wherein the hydrogel film includes chitosan.10. The apparatus of wherein the hydrogel film includes urea.11. The apparatus of wherein the hydrogel film includes at least one crystal.121. The apparatus of wherein the at least one crystal is (a) dendritically branched claim 11 , and (b) at least micron in diameter.13. The apparatus of wherein the at least one crystal comprises cyclodextrin.14. An ...

BIFUNCTIONAL MODIFIED BIOPOLYMER BASED POLYMERS AND HYDROGELS OBTAINABLE FROM SUCH BIFUNCTIONAL MODIFIED BIOPOLYMER BASED POLYMERS

The invention relates to a bifunctional modified biopolymer based polymer, comprising at least one polymer chain comprising n first functional groups and m second functional groups. The first functional groups comprise groups able of being radically cross-linked following a free radical chain- growth polymerisation. The second functional groups comprise groups able to thiol-ene crosslinking. Preferred bifunctional modified biopolymer based polymers comprise bifunctional modified gelatin and bifunctional modified collagen. The invention further relates to a method to prepare such a bifunctional modified biopolymer based polymer and to a method to prepare a hydrogel starting from such bifunctional modified biopolymer based polymer. Furthermore the invention relates to hydrogels obtainable starting from such bifunctional modified biopolymer based polymers and to the use of such hydrogels. 115-. (canceled)16. A bifunctional modified biopolymer based polymer comprising at least one polymer chain , wherein:the at least one polymer chain comprises n first functional groups and m second functional groups, with both n and m not being zero;the first functional groups comprise groups that are radically cross-linkable following a free radical chain-growth polymerization; andthe second functional groups comprise thiol-ene cross-linkable groups that remain unreacted during free radical chain-growth polymerization of the first functional groups.17. The bifunctional modified biopolymer based polymer of claim 16 , wherein the biopolymer based polymer is selected from the group consisting of polypeptides claim 16 , proteins claim 16 , polysaccharides claim 16 , nucleic acids claim 16 , gelatins claim 16 , collagens claim 16 , alginates claim 16 , dextrans claim 16 , agarose claim 16 , glycosaminoglycans claim 16 , chitosans and carrageenans claim 16 , derivates thereof claim 16 , recombinant analogues thereof claim 16 , and synthetic analogues thereof.18. The bifunctional modified ...

CYCLIC RGD CELL-BINDING MOTIF AND USES THEREOF

A recombinant fusion protein is comprising a spider silk fragment and a cyclic RGD cell-binding motif with selectivity for integrins, such as for α5β1 integrins. The fusion protein is useful as a cell scaffold material and for the cultivation of cells displaying integrins on their cell surface. 120.-. (canceled)22. A recombinant fusion protein according to claim 21 , wherein Xis G or A.23. A recombinant fusion protein according to claim 21 , wherein Xis G.24. A recombinant fusion protein according to claim 21 , wherein Xis S.25. A recombinant fusion protein according to claim 21 , wherein Xis G or P.26. A recombinant fusion protein according to claim 25 , wherein Xis P.27. A recombinant fusion protein according to claim 21 , wherein Xis G or A.28. A recombinant fusion protein according to claim 27 , wherein Xis A.29. A recombinant fusion protein according to wherein the cell-binding motif is comprising the amino acid sequence CTGRGDSPAC (SEQ ID NO: 10).30. A recombinant fusion protein according to claim 21 , wherein the cell-binding motif has selectivity for α5β1 integrins.31. A recombinant fusion protein according to claim 21 , wherein the spidroin fragment is comprising the protein moiety CT claim 21 , whereinCT is a fragment of from 70 to 120 amino acid residues, having at least 70% identity to any one of SEQ ID NO: 3 and 29-59.32. A recombinant fusion protein according to claim 31 , wherein CT has at least 80% identity to any one of SEQ ID NO: 3 and 29-59.33. A recombinant fusion protein according to claim 31 , wherein CT has at least 80% identity to SEQ ID NO: 3.34. A recombinant fusion protein according to claim 21 , wherein the spidroin fragment is further comprising the protein moiety REP claim 21 , wherein{'sub': n', 'n', 'n', 'n, 'REP is a repetitive fragment of from 70 to 300 amino acid residues, selected from the group consisting of L(AG)L, L(AG)AL, L(GA)L, and L(GA)GL, wherein'}n is an integer from 2 to 10;each individual A segment is an amino acid ...

Intraocular implant and method for producing an intraocular implant

An intraocular implant, such as a corneal implant, an intraocular lens or an IOL carrier matrix, which has a dimensionally stable lattice structure and a corresponding method for producing an intraocular implant. The intraocular implant and method for producing an intraocular implant counteract metabolic problems, and thus also limited functional compatibility, and facilitates long-term tolerance. The intraocular implant has a dimensionally stable lattice structure designed in such a way that it permits permeability for small molecules and/or supports the mobility of endogenous cells in the implant.

SKIN SUBSTITUTES AND METHODS FOR HAIR FOLLICLE NEOGENESIS

This invention provides compositions in the form of skin substitutes comprising epithelial cells and mesenchymal cells, wherein the mesenchymal cells are not isolated from the occipital or nape region of the scalp, as well as methods for using the same. 1113-. (canceled)114. A skin substitute comprising epithelial cells and mesenchymal cells , wherein the mesenchymal cells area. neural crest-derived mesenchymal cells orb. scalp- or face-derived mesenchymal cells, wherein the mesenchymal cells are not derived from an occipital or nape region of the scalp.115. The skin substitute of claim 114 , wherein the epithelial cells are keratinocytes.116. The skin substitute of claim 114 , wherein the mesenchymal cells are hair follicle dermal cells.117. The skin substitute of claim 116 , wherein the hair follicle dermal cells are dermal papilla cells or dermal sheath cells.118. The skin substitute of claim 116 , wherein the hair follicle dermal cells are derived from scalp or face.119. The skin substitute of claim 118 , wherein the hair follicle dermal cells are derived from a frontal claim 118 , temporal claim 118 , mid scalp claim 118 , top of head claim 118 , vertex claim 118 , or parietal region of the scalp.120. The skin substitute of claim 114 , wherein the epithelial cells are from a first or second passage.121. The skin substitute of claim 114 , wherein the mesenchymal cells are from a first claim 114 , second claim 114 , third claim 114 , or fourth passage.122. The skin substitute of claim 120 , wherein the epithelial cells are passaged in keratinocyte-conditioned medium.122. The skin substitute of claim 121 , wherein the mesenchymal cells are passaged in keratinocyte-conditioned medium.123. The skin substitute of claim 114 , wherein the epithelial cells and the mesenchymal cells are human.124. The skin substitute of claim 114 , further comprising collagen.125. A method for inducing hair follicle growth or hair follicle neogenesis claim 114 , comprising delivering to ...

METHOD FOR PREPARING TRANSPARENT COLLAGEN MATRICES

Disclosed is a method for preparing a transparent fibrillated collagen matrix capable of being used as a tissue substitute in the production of a tissue or an artificial organ, in particular for a cornea substitute. 1. Method for preparing a transparent matrix of fibrillated collagen comprising the following steps:a) a step of preparing a collagen acid solution in an aqueous solventb) a step of concentrating the collagen acid solutionc) a step of fibrillogenesis of the collagen matrix whereinthe concentration step is carried out until a collagen concentration is obtained comprised between 43 and 50 mg/ml.2. Method according to claim 1 , wherein the concentration step is carried out so as to limit claim 1 , advantageously to avoid claim 1 , shearing stresses.3. Method according to claim 1 , wherein the concentration step is carried out until a collagen concentration is obtained comprised between 43.5 and 47 mg/mL claim 1 , preferentially of the order of 45 mg/mL.4. Method according to claim 1 , wherein the collagen acid solution is constituted by an aqueous acetic acid solution.5. Method according to claim 3 , wherein the concentration of the initial acid solution claim 3 , before the concentration step claim 3 , is comprised between 0.01 mg/ml and 5 mg/mL claim 3 , advantageously comprised between 0.5 and 3 mg/mL.6. Method according to claim 1 , wherein the concentration step is carried out by evaporation or by dialysis.7. Method according to claim 1 , wherein the fibrillogenesis step consists of bringing the collagen matrix into contact with a basic gas phase or a neutral or basic liquid.8. Method according to claim 7 , wherein the fibrillogenesis step is carried out by bringing the collagen matrix into contact with ammonia vapours.9. Method according to claim 1 , also comprising a step of washing the fibrillated collagen matrix in a buffer solution claim 1 , for example phosphate buffered solution.10. Method for preparing a transparent collagen matrix according to ...

SEGREGATION OF OILS IN THE FRACTIONATION OF ASPIRATED ADIPOSE TISSUES

Adipose is obtained from aspirated adipose by centrifugal separation of adipose from tumescent fluids and oils released from damaged adipose cells. Aspirated adipose is placed in a container having therein a disk that floats on adipose and takes up the released oils whereby they are unlikely to remix with the adipose during handling after centrifugation. The disk also adheres to the adipose by entraining part of the adipose layer. 1. A container forming a cavity for separating aspirated adipose fluids into components based on relative densities and having therein a disk movable within said cavity , said disk being made of a material and configured such that it floats on a layer of adipose that has been separated from oils released from damaged adipose cells and prevents substantially remixing of said oils with said adipose during handling of said container.2. A container according to wherein said material adheres to at least a portion of said layer of adipose.3. A container according to wherein said material is capable of taking up oils released from damaged adipose cells.4. A container according to wherein said material adheres to at least a portion of said layer of adipose.5. A container according to wherein said material is porous and the diameters of said pores are from 20 to 170 microns.6. A container according to wherein the diameters of said pores are from 90 to 130 microns.7. A container according to wherein said material is plastic.8. A container according to wherein said plastic is polyethylene.9. A container according to wherein the density of said material is between about 0.905 and 0.925.10. A container according to wherein said container comprises an inlet at one end for introducing said aspirated adipose fluids into said cavity.11. A container according to wherein said container further comprises a piston movable along said cavity for drawing said aspirated adipose fluids into said cavity claim 1 , and a handle removably attached to said piston for ...

METHOD FOR MANUFACTURING RING-SHAPED BONE GRAFTING SUBSTITUTE

Provided is a method for manufacturing a ring-shaped bone grafting substitute. The method for manufacturing a ring-shaped bone grafting substitute includes a biodegradable polymer providing step of providing a biodegradable polymer, a molding material providing step of providing a molding material in which the biodegradable polymer and a bone material are mixed; a molding material injection step of injecting the molding material into a ring-shaped mold such that a hole is formed in the center thereof; and ring-shaped bone grafting substitute molding step of freeze-drying the molding material having been injected into the ring-shaped mold at a temperature lower than a predetermined reference temperature, thereby molding the resultant into a ring-shaped bone grafting substitute. 1. A method for manufacturing a ring-shaped bone grafting substitute , the method comprising:a biodegradable polymer providing step of providing a biodegradable polymer;a molding material providing step of providing a molding material by mixing the biodegradable polymer with a bone material;a molding material injection step of injecting the molding material into a ring-shaped mold having a ring shape to form a hole at a center; anda ring-shaped bone grafting substitute molding step of molding a ring-shaped bone grafting substitute having a ring shape by freeze-drying the molding material injected into the ring-shaped mold at a temperature lower than a predetermined reference temperature.2. The method of claim 1 , further comprising claim 1 , after the ring-shaped bone grafting substitute molding step claim 1 , a ring-shaped bone grafting substitute hot air drying step of drying claim 1 , by using hot air claim 1 , the ring-shaped bone grafting substitute that has been completely molded.3. The method of claim 2 , further comprising claim 2 , before the ring-shaped bone grafting substitute hot air drying step:a ring-shaped bone grafting substitute cutting step of cutting the ring-shaped bone ...

EPOXIDIZED NATURAL RUBBER COMPOSITE AND PREPARATION PROCESS THEREOF

The present disclosure provides an epoxidized natural rubber composite and a preparation process thereof, and relates to the technical field of rubber materials. The epoxidized natural rubber composite provided by the present disclosure comprises the following preparation raw materials in parts by weight: 100 parts of epoxidized natural rubber, 1˜30 parts of peanut meal, 0.05˜0.8 parts of surfactants, 0.1˜4 parts of coagulant and 0.2˜12 parts of vulcanization processing aids. The present disclosure utilizes essential amino acids and non-essential amino acids contained in peanut meal to improve the aging resistance of the epoxidized natural rubber. After hot air aging, ozone aging and ultraviolet aging treatments, both the tensile strength retention rate and the elongation at break retention rate of the epoxidized natural rubber composites of the present disclosure can be kept above 83%. 1. An epoxidized natural rubber composite , wherein , it comprises the following preparation raw materials in parts by weight:100 parts of epoxidized natural rubber, 1˜30 parts of peanut meal, 0.05˜0.8 parts of surfactants, 0.1˜4 parts of coagulant, and 0.2˜12 parts of vulcanization processing aids.2. The epoxidized natural rubber composite according to claim 1 , wherein claim 1 , the epoxidization degree of the epoxidized natural rubber is 2˜50.3. The epoxidized natural rubber composite according to claim 1 , wherein claim 1 , the particle size of the peanut meal is 0.30˜0.45 mm.4. The epoxidized natural rubber composite according to claim 1 , wherein claim 1 , the surfactants include at least one of sodium dodecyl sulfonate claim 1 , sodium dodecyl sulfate claim 1 , sodium lignin sulfonate and calcium lignin sulfonate.5. The epoxidized natural rubber composite according to claim 1 , wherein claim 1 , the coagulant is selected from the group consisting of methanol and ethanol.6. The epoxidized natural rubber composite according to claim 1 , wherein claim 1 , the vulcanization ...

USE OF 2,4-DIHALO-6-SUBSTITUTED-1,3,5-TRIAZINES AND DERIVATIVE THEREOF AS CONDENSATION, CROSS-LINKING, TANNING, GRAFTING AND CURING AGENTS

Use of 2,4-dihalo-6-substituted-1,3,5-triazines as condensing, cross-linking, tanning, grafting, curing agents for the production of amides, esters, thioesters, and stabilized collagen and leather, CMC (carboxymethyl cellulose), synthetic and natural polymers. The process enables to obtain non-toxic and totally free of heavy metals products characterized by Tg values between 80° C. and 100° C. 122-. (canceled)24. The process according to claim 23 , wherein the 2 claim 23 ,4 claim 23 ,6-substituted-1 claim 23 ,3 claim 23 ,5-triazine of formula (I) is a 2 claim 23 ,4-dihalo-1 claim 23 ,3 claim 23 ,5-triazine claim 23 , wherein Rand Rare independently selected from the group consisting of Cl claim 23 , Br and F.25. The process according to claim 23 , wherein Ris selected from the group consisting of OCH claim 23 , OCHCH claim 23 , OCH(CH) claim 23 , OCHCHCH claim 23 , and OCHCHCHCH.26. The process according to claim 23 , wherein Ris selected from the group consisting of OCH claim 23 , OCHCH claim 23 , OCHCHCH.27. The process according to claim 23 , wherein Ris selected from the group consisting of N(CH) claim 23 , N(CHCH) claim 23 , N[CH(CH)] claim 23 , N(CHCHCHCH)and N(CH).28. The process according to claim 23 , wherein the reacting step (a) is carried out at a temperature between 0° C. and 70° C. for 15 minutes to 48 hours.29. The process according to claim 23 , wherein the solvent is selected from the group consisting of an aliphatic ether claim 23 , a halogenate claim 23 , an alcohol claim 23 , a ketone claim 23 , an ester claim 23 , an aromatic hydrocarbon claim 23 , an aliphatic hydrocarbon claim 23 , an amide claim 23 , a carbonate claim 23 , DMSO and water.30. The process according to claim 23 , wherein claim 23 , when Rand Rare both Cl claim 23 , Br claim 23 , or F in formula (I) claim 23 , step (a) further comprises the presence of a linear or branched alkyl tertiary amine claim 23 , aryl tertiary amine or heterocyclic tertiary amine.31. The process according ...

PATCH FOR REGENERATING BIOLOGICAL TISSUES AND METHOD FOR PRODUCING SAME

Patch () for regenerating biological tissues in patients and method of manufacture associated with the same, comprising a collagen membrane () which comprises cells with a regenerative character; and at least one reinforcement element () configured to increase the rigidity of said membrane (), preventing the deformation of said membrane () during the handling thereof; wherein said reinforcement element () can be a perimeter frame () and/or a crossed attachment () between the ends of said membrane (); which provides a patch () which can be applied to any type of biological organ with maximum assurances of success as well as reducing the application time. 1123322a,b. A patch () for regenerating biological tissues in patients comprising a collagen membrane () which comprises cells with a regenerative character and is characterised in that it also comprises a reinforcement element () configured to increase the rigidity of said membrane () , preventing the deformation of said membrane () during the handling thereof.213332a,ba. The patch () according to claim 1 , characterised in that said at least one reinforcement element () comprises a perimeter frame () belonging to said membrane ().313332a,bb. The patch () according to any of the preceding claims claim 1 , characterised in that said at least one reinforcement element () comprises a crossed attachment () between ends of said membrane ().41332a,b. The patch () according to any of the preceding claims claim 1 , characterised in that said at least one reinforcement element () is manufactured with the same material as said membrane ().51. A method of manufacturing a patch () for regenerating biological tissues in patients claim 1 , characterised in that it comprises the following steps:{'b': '2', 'a) manufacturing a collagen membrane ();'}{'b': 3', '3, 'i': a,', 'b, 'b) manufacturing at least one reinforcement element ();'}{'b': 3', '3', '2, 'i': a,', 'b, 'c) placing said at least one reinforcement element () with respect ...

Cosmetic Sponge And Method For Providing A Cosmetic Sponge

This invention relates to a cosmetic sponge and a method of providing a cosmetic sponge incorporating a non-denatured collagen and other additives for skin care, cleaning, and cosmetic application. 1. A cosmetic sponge comprising a polymer foam , a non-denatured collagen , and at least one additive , and wherein said non-denatured collagen comprises a fat content.2. The cosmetic sponge of wherein said non-denatured collagen is prepared under pH conditions ranging from approximately 13 to approximately 3.3. The cosmetic sponge of wherein said at least one additive is selected from the group consisting of: skin care agents claim 1 , hydrocolloid absorptive agents claim 1 , medicaments claim 1 , proteins claim 1 , enzymes claim 1 , nucleic acids claim 1 , vitamins claim 1 , soaps claim 1 , hemostatic agents claim 1 , antibacterial agents claim 1 , antifungal agents claim 1 , surfactants claim 1 , pH buffers claim 1 , mineral salts claim 1 , trace elements claim 1 , plant extracts claim 1 , animal extracts claim 1 , disinfecting and sterilizing agents claim 1 , and combinations thereof.4. The cosmetic sponge of wherein said sponge further comprises an agent from the group consisting of: a cross-linking agent claim 1 , a catalyst claim 1 , a surfactant claim 1 , and combinations thereof.5. The cosmetic sponge of wherein said polymer is a superabsorbent polymer.6. A cosmetic sponge comprising a polymer foam claim 1 , a non-denatured collagen claim 1 , and at least one additive claim 1 , and wherein said non-denatured collagen comprises a protein content.7. The cosmetic sponge of claim 6 , wherein said sponge is a reaction product of a mixture comprising a predetermined amount of non-denatured collagen claim 6 , a predetermined amount of water claim 6 , a predetermined amount of a prepolymer claim 6 , and at least one additive.8. The cosmetic sponge of wherein said sponge further comprises an agent from the group consisting of: a cross-linking agent claim 6 , a catalyst ...

Preparation and/or Formulation of Proteins Cross-Linked with Polysaccharides

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

High density fibrous polymers suitable for implant

This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

Methods for Localized Modification of Tissue Products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties. 1. A method for treating a tissue matrix , comprising:selecting a collagen-containing tissue matrix; andcross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix.2. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.3. The method of claim 1 , wherein the tissue matrix comprises a dermal tissue matrix.4. The method of claim 1 , wherein the tissue matrix is derived from a tissue selected from fascia claim 1 , pericardial tissue claim 1 , dura claim 1 , umbilical cord tissue claim 1 , placental tissue claim 1 , cardiac valve tissue claim 1 , ligament tissue claim 1 , tendon tissue claim 1 , arterial tissue claim 1 , venous tissue claim 1 , neural connective tissue claim 1 , urinary bladder tissue claim 1 , ureter tissue claim 1 , and intestinal tissue.5. The method of claim 1 , wherein cross-linking select portions of the tissue matrix comprises applying a fluid containing a cross-linking agent to the select portions.6. The method of claim 5 , wherein applying a fluid containing a cross-linking agent to the select portions comprises:providing a solid surface having one or more channels configured to allow fluid to flow therethough;contacting the tissue matrix with the surface; andcausing fluid containing a cross-linking agent to flow through the channels.7. The method of claim 6 , wherein the one or more channels have at least one of a serpentine pattern claim 6 , a web-like pattern claim 6 , a circular pattern claim 6 , a grid pattern claim 6 , and a linear pattern.8. The method of claim 5 , wherein the cross-linking agent comprises at ...

PREPARATION METHOD AND USAGE METHOD FOR CARTILAGE TISSUE RECOVERY COLLAGEN

The present invention relates to a method of manufacturing collagen for restoring cartilage tissue usable for a joint in an injection manner, and a usage method thereof. The present invention provides a method of obtaining a high-concentration collagen-solution injection by aseptically filling an injection container with collagen separated from pig skin tissue, and a method of using the high-viscosity collagen loaded into the injection container for the purpose of cartilage restoration. Cartilage tissue regeneration is effectively induced when tissue restoration is implemented with respect to a cartilage-deficient portion using collagen, which is a biocompatible material, in a form that is capable of being injected into an application site with an injection needle without a surgical incision. Accordingly, restoration and regeneration of cartilage are easily and quickly induced in an animal, excluding a human, while relieving the burden related to surgery. 1. A method of manufacturing collagen for restoring a cartilage tissue , in which a pig skin tissue is fragmentized , washed , and subjected to enzyme treatment , a collagen is separated therefrom , and high-concentration collagen aseptically loaded into an injection container is obtained through salt treatment , sterilization by filtration , concentration , and filling processes , the method comprising:a process of separating the collagen from the pig skin tissue and filling the injection container with the collagen, the process comprising:washing the skin tissue separated from a pig using ethanol and sodium hydroxide, followed by fragmentizing;mixing the fragmentized tissue with an acidic solution containing an enzyme, followed by agitation to perform a reaction;adding NaCl in order to obtain the collagen separated from the tissue;performing passing through a membrane filter to separate collagen molecules, followed by passing through a filter to obtain the sterile collagen;performing agglomeration of the collagen ...

BINDERS AND MATERIALS MADE THEREWITH

Binders to produce or promote cohesion in non-assembled or loosely assembled matter. 1160.-. (canceled)161. A thermal or acoustical fiberglass insulation material comprising:(a) a collection of mineral fibers; and{'sup': 3', '3, '(b) a binder disposed on the collection of mineral fibers, wherein the binder consists essentially of i) at least one reaction product of a reducing sugar reactant and an amine reactant, ii) a silicon-containing coupling agent, and iii) optionally, a corrosion inhibitor, wherein the fiberglass material comprises less than about 99% by weight and more than about 75% by weight mineral fibers, and wherein the fiberglass material has a density of from about 0.4 lbs/ftto about 6 lbs/ft.'}162. The fiberglass material of claim 161 , wherein the amine reactant is an ammonium salt of a polycarboxylic acid.163. The fiberglass material of claim 161 , wherein the amine reactant is an ammonium salt of a monomeric polycarboxylic acid.164. The fiberglass material of claim 161 , wherein the density is from about 0.75 lbs/ftto about 2.5 lbs/ft.165. The fiberglass material of claim 161 , wherein the density is from about 2.25 lbs/ftto about 4.25 lbs/ft.166. The fiberglass material of claim 161 , wherein the density is from about 0.4 lbs/ftto about 1.5 lbs/ft.167. The fiberglass material of claim 161 , wherein the density is from about 3.75 lbs/ftto about 5.2 lbs/ft.168. A thermal or acoustical fiberglass insulation material comprising:(a) a collection of mineral fibers; and{'sup': 3', '3, '(b) a binder disposed on the collection of mineral fibers, the binder consisting essentially of i) a mixture of Maillard reactants, ii) a silicon-containing coupling agent, and iii) optionally, a corrosion inhibitor, wherein the fiberglass material comprises less than about 99% by weight and more than about 75% by weight mineral fibers, and wherein the fiberglass material has a density in the range from about 0.4 lbs/ftto about 6 lbs/ft.'}169. A thermal or acoustical ...

Methods of coating a construct with methylated collagen

A double-structured tissue implant and a method for preparation and use thereof for implantation into tissue defects. The double-structured tissue implant comprising a primary scaffold and a secondary scaffold consisting of a soluble collagen solution in combination with a non-ionic surfactant generated and positioned within the primary scaffold. A stand alone secondary scaffold implant or unit. A process for preparation of the double-structured implant or the stand alone secondary scaffold comprising lyophilization and dehydrothermal treatment. 120.-. (canceled)21. A method for depositing methylated collagen on a construct , the method comprising:obtaining a construct;contacting the construct with a composition comprising methylated collagen and a surfactant; andstabilizing the composition on the construct.22. The method of claim 21 , wherein the surfactant is a non-ionic surfactant.23. The method of claim 22 , wherein the non-ionic surfactant is a polymeric compound.24. The method of claim 21 , wherein the surfactant is an ionic surfactant.25. The method of claim 21 , wherein the composition is soluble in water.26. The method of claim 21 , wherein the construct is a scaffold.27. The method of claim 21 , wherein the construct is a container or a mold.28. The method of claim 21 , wherein the composition is a solution claim 21 , a suspension or an aqueous gel.29. The method of claim 21 , wherein the contacting step further comprises steps selected from the group consisting of absorbing claim 21 , soaking claim 21 , wicking claim 21 , and submerging.30. The method of claim 21 , wherein the contacting step comprises electrophoresis.31. The method of claim 21 , wherein the composition comprises cells.32. The method of claim 21 , wherein the composition comprises at least one pharmaceutical agent.33. The method of claim 32 , wherein the pharmaceutical agent is a drug.34. The method of claim 21 , wherein the composition comprises a growth modulator.35. The method of claim ...

ENGINEERED LEATHER AND METHODS OF MANUFACTURE THEREOF

Engineered animal skin, hide, and leather comprising a plurality of layers of collagen formed by cultured animal collagen-producing (e.g., skin) cells. Layers may be formed by elongate multicellular bodies comprising a plurality of cultured animal cells that are adhered and/or cohered to one another; wherein the elongate multicellular bodies are arranged to form a substantially planar layer for use in formation of engineered animal skin, hide, and leather. Further described herein are methods of forming engineered animal skin, hide, and leather utilizing said layers of animal collagen-producing cells. 1. A method of producing an engineered leather , the method comprising:culturing one or more types of collagen-producing cells in vitro;forming a plurality of sheets of extracellular matrix including collagen produced by the one or more types of collagen-producing cells;layering the plurality of sheets to form a body having a volume;allowing the layered sheets to fuse; andprocessing the body by tanning to modify the collagen.2. The method of claim 1 , further comprising preparing a plurality of elongate or spherical multicellular bodies comprising said one or more types of collagen-producing cells claim 1 , wherein the collagen-producing cells are cohered to one another.3. The method of claim 1 , wherein forming the plurality of sheets comprises forming a plurality of planar layers comprising adjacently arranging a plurality of elongate multicellular bodies claim 1 , wherein said elongate multicellular bodies are fused to form a planar layer.4. The method of claim 3 , wherein forming comprises automated deposition of multicellular bodies into said layers without a structural scaffold.5. The method of claim 1 , wherein arranging comprises culturing cells on a support to form a substantially planar layer of collagen above and between the cells.6. The method of claim 1 , wherein allowing the layers to fuse takes place over about 2 hours to about 24 hours.7. The method of ...

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. A hydrogel that comprises molecular pores, the hydrogel comprising: one or more crosslinked polymers formed about a plurality of pre-formed molecular crystals, wherein the crystals are formed while the polymer is in an uncrosslinked form and the molecular crystals form a porous structure within the polymers during the crosslinking of the polymers. This application is a continuation of U.S. patent application Ser. No. 16/597,106, filed Oct. 9, 2019, which is a continuation of U.S. patent application Ser. No. 15/890,719, filed Feb. 7, 2018, now U.S. Pat. No. 10,442,911, issued Oct. 15, 2019, which is a continuation of U.S. patent application Ser. No. 15/135,978, filed Apr. 22, 2016, now U.S. Pat. No. 9,896,561, issued Feb. 20, 2018, which is a continuation of U.S. patent application Ser. No. 14/277,170, filed May 14, 2014, now U.S. Pat. No. 9,320,827, issued Apr. 26, 2016, which is a continuation of U.S. patent application Ser. No. 13/909,707, filed Jun. 4, 2013, now U.S. Pat. No. 8,728,499, issued May 20, 2014, which is a continuation of U.S. patent application Ser. No. 12/919,667, filed Aug. 26, 2010, now U.S. Pat. No. 8,668,863, issued Mar. 11, 2014, which claims priority to Patent Cooperation Treaty Application Serial No. PCT/US2009/035257, filed Feb. 26, 2009, which claims priority to U. ...

USE OF NITROGEN-CONTAINING COMPOUNDS AS PLASTICIZERS FOR PEPTIDE-BASED BIOPOLYMERS AND USES THEREOF

A novel method of reducing the melting point of a peptide-based biopolymer using a nitrogen-containing compound as a plasticizer is provided. The peptide-based biopolymer can be keratin or silk. The nitrogen-containing compound can be one or more amino acids or other nitrogen-containing compounds (except urea), all of which have a melting temperature above approximately 133° C., the decomposition temperature of urea. Pellets made using this novel process can be used as animal feed and soil amendments (fertilizer) to increase the adsorption of amino acids in the animal or in the soil, respectively. 1. A method of processing a peptide-based biopolymer comprising mixing said peptide-based biopolymer with a nitrogen-containing compound wherein said melting point of said nitrogen-containing compound is greater than the melting point of urea.2. The method of further comprising heating said mixture of said peptide-based biopolymer and said nitrogen-containing compound.3. The method of wherein said peptide-based biopolymer is keratin or silk.4. The method of wherein said nitrogen-containing compound is selected from the group consisting of an amino acid claim 1 , biuret claim 1 , melamine and a combination thereof.5. The method of claim 4 , wherein said peptide-based biopolymer is keratin claim 4 , and wherein said amino acid is selected from the group consisting of proline claim 4 , lysine claim 4 , serine claim 4 , glycine claim 4 , and combinations thereof.6. The method of wherein said peptide-based biopolymer is keratin and wherein said nitrogen-containing compound is selected from the group consisting of biuret claim 4 , melamine claim 4 , proline claim 4 , lysine claim 4 , serine claim 4 , glycine claim 4 , and combinations thereof.7. The method of wherein the ratio of the weight of said peptide-based biopolymer to the weight of said nitrogen-containing compound ranges between approximately 1%/99% to approximately 15%/85%.8. The method of wherein said ratio is ...

Method and Compositions for Synthesizing Improved Silk Fibers

The present disclosure provides methods and compositions for directed to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers (including advantageously, microfibers) comprising these proteins that recapitulate many properties of natural silk. The recombinant microorganisms can be used for the commercial production of silk-like fibers. 1. A proteinaceous block co-polymer , comprising:a polypeptide, the polypeptide comprising from 2 to 8 concatenated repeats of SEQ ID NO: 1396 or circularly permuted variants thereof.2. The proteinaceous block co-polymer of claim 1 , wherein the polypeptide comprises a property selected from the group consisting of an alanine composition from 12 to 40% claim 1 , a glycine composition from 25 to 50% claim 1 , a proline composition from 9 to 20% claim 1 , a β-turn composition from 15 to 37% claim 1 , a GPG amino acid motif content from 18 to 55% claim 1 , and a poly-alanine amino acid motif content from 9 to 35%.3. The proteinaceous block co-polymer of claim 1 , consisting of: 3 concatenated repeats of SEQ ID NO: 1396.4. A fiber comprising the block co-polymer of .5. The fiber of claim 4 , comprising a circular cross-section and a diameter from 4.48 to 12.7 μm.6. The fiber of claim 4 , wherein the fiber has a yield stress from 24 to 172 MPa.7. The fiber of claim 4 , wherein the fiber has a maximum stress from 54 to 310 MPa.8. The fiber of claim 4 , wherein the fiber has a breaking strain from 2 to 200%.9. The fiber of claim 4 , wherein the fiber has an initial modulus from 1617 to 5820 MPa.10. The fiber of claim 4 , wherein the fiber has a toughness value from 0.5 MJ/mto 59.2 MJ/m.11. An expression construct encoding the proteinaceous block co-polymer of .12. The expression construct of claim 11 , further comprising a secretion signal operatively linked to the coding sequence for the block copolymer polypeptide.13. The expression construct of ...

DRIED IMPLANT COMPOSITION AND INJECTABLE AQUEOUS IMPLANT FORMULATION

A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation for use in a method of oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation for use in oral tissue regeneration. 1. A method of treating a subject with an injectable aqueous implant formulation , wherein the subject is in need of oral tissue regeneration , comprising implanting the injectable aqueous implant formulation of in an oral cavity of the subject by extruding the injectable aqueous implant formulation of through a tapering system and a gauge 18 cannula (having an inner diameter of 0.838 mm) positioned in the implantation site.2. The method of claim 1 , further comprising claim 1 , before said implanting:a) providing a dried implant composition that consists essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5; andb) rehydrating 25-45 w/w % of the dried implant composition in a pharmaceutically acceptable aqueous vehicle and mixing to form the injectable rehydrated aqueous implant formulation.3. The method of claim 2 , wherein the dried implant composition has a w/w ratio of hydroxyapatite to collagen of from 2.5 to 4.2.4. The method of claim 2 , wherein in the dried implant composition the hydroxyapatite ...

Compositions and methods for selectively sequestering metal ions

Compositions and methods for the selective sequestration of metal ions are generally described.

RESIDUAL SOY FLOUR SUGARS AS CROSSLINKERS FOR ENHANCING MECHANICAL PERFORMANCE OF PROTEIN FIBERS

Disclosed is a method of crosslinking protein fibers, including wool fibers, by (i) providing a crosslinking agent including an oxidized sugar mixture having a plurality of different oxidized sugars of different molecular lengths and having at least two aldehyde groups (e.g., oxidized soy flour sugars); and (ii) infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked. This method yields a population of crosslinked protein fibers, where the protein molecules of the non-crosslinked protein fibers include amine groups that react with the aldehyde groups of the oxidized sugars to achieve the crosslinking of the protein molecules to yield the crosslinked protein fibers. 1. A method of crosslinking protein fibers , said method comprising:providing a crosslinking agent comprising an oxidized sugar mixture comprising a plurality of different oxidized sugars of different molecular lengths and having at least two aldehyde groups; andinfiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers,wherein the protein molecules of the non-crosslinked protein fibers comprise amine groups that react with the aldehyde groups of the oxidized sugars to achieve the crosslinking of the protein molecules to yield the crosslinked protein fibers.2. The method according to claim 1 , wherein said infiltrating step is carried out at a temperature and for a length of time sufficient to yield crosslinked protein fibers having improved tensile properties selected from the group consisting of increased tensile strength and increased Young's modulus compared to the non-crosslinked protein fibers.3. The method according to claim 2 , wherein ...

Hydrolyzed collagen compositions and methods of making thereof

Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.

RENEWABLE SELF-HEALING CAPSULE SYSTEM

A renewable material for releasing a self-healing agent includes a renewable polymeric substrate with capsules and a reactant dispersed in the renewable polymeric substrate. The capsules may be formed from a first renewable shell polymer and may enclose the renewable self-healing agent. The reactant may be suitable for reacting with the renewable self-healing agent to form a polymer. 1. A method for creating a renewable self-healing material , comprising:creating a microemulsion having a continuous phase and a first dispersed phase, wherein the continuous phase includes a first renewable shell polymer and a first solvent, and the first dispersed phase includes a renewable self-healing agent;decreasing the solubility of the first renewable shell polymer in the continuous phase to form a second dispersed phase, wherein the second dispersed phase has a higher concentration of the first shell polymer than the continuous phase;forming a capsule around the first dispersed phase of self-healing agent, wherein the capsule contains the first renewable shell polymer; anddispersing the capsule and a reactant into a renewable polymeric substrate, wherein the reactant is suitable for reacting with the renewable self-healing agent to form a polymer.2. The method of claim 1 , wherein the first renewable shell polymer is from the group consisting of collagen claim 1 , starch claim 1 , gum arabic claim 1 , gelatin claim 1 , dextrin claim 1 , cellulose claim 1 , and casein.3. The method of claim 1 , wherein the renewable polymeric substrate is from the group consisting of sugars claim 1 , vegetable oils claim 1 , lignin claim 1 , cellulose claim 1 , suberin claim 1 , citric acid claim 1 , and tartaric acid.4. The method of claim 1 , wherein the reactant is an amine or a Lewis acid.5. The method of claim 1 , wherein decreasing the solubility involves an action from the group consisting of changing the pH of the microemulsion claim 1 , changing the temperature of the microemulsion ...

MATRICES COMPRISING A MODIFIED POLYSACCHARIDE

The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group. 1. A matrix comprising a modified polysaccharide consisting of repeating disaccharide units , whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized to a carboxylic acid group.2. The matrix according to claim 1 , wherein in 20-99% of the disaccharide repeat units claim 1 , the primary alcohol group is oxidized to the carboxylic acid group.3. The matrix according to claim 2 , wherein in 50-95% of the repeat disaccharide units claim 2 , the primary alcohol group is oxidized to the carboxylic acid group.4. The matrix according to claim 1 , wherein the modified polysaccharide is blended with an unmodified polysaccharide.5. The matrix according to claim 4 , wherein the modified polysaccharide and/or the not modified polysaccharide is agarose.6. The matrix according to claim 1 , wherein the polysaccharide is of natural origin.7. The matrix according to claim 4 , wherein either the modified polysaccharide or the non-modified polysaccharide is selected from the group consisting of a member of the carrageenan family claim 4 , hyaluronic acid claim 4 , heparin sulfate claim 4 , dermatan sulfate claim 4 , chondroitin sulfate claim 4 , alginate claim 4 , chitosan claim 4 , pullulan and agarose.8. The matrix according to claim 1 , wherein the carboxylic group derived from the oxidation of the primary alcohol group is covalently coupled with a peptide sequence.9. The matrix according to claim 8 , wherein the peptide sequence is selected from the group consisting of the cell adhesion sequence arginin-glycin-aspartic acid claim 8 , the peptide sequences IKVAV and YIGSR or a protein selected from collagen claim 8 , collagen fragments claim 8 , fibronectin and mixtures thereof.10. The matrix according to claim 1 , ...

COMPOSITE TISSUE-ENGINEERED INTERVERTEBRAL DISC WITH SELF-ASSEMBLED ANNULAR ALIGNMENT

The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs. 1. A method of fabricating a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal , said method comprising:providing a first gel comprising a first population of living cells that secrete a hydrophilic protein;forming the first gel into a predetermined shape and size;providing a second gel comprising a second population of living cells and type I collagen;contacting the formed first gel with the second gel at a region that extends circumferentially around the first gel; andstoring the first and second gels under conditions effective for the collagen in the second gel to align circumferentially around the first gel by self-assembly of collagen due to cell-mediated gel contraction in the second gel, wherein the first gel forms a nucleus pulposus structure and the second gel forms an annulus fibrosus structure surrounding and in contact with the nucleus pulposus structure, thereby fabricating a tissue-engineered IVD suitable for total disc replacement in a mammal.2. The method according to claim 1 , wherein the first gel is an alginate gel comprising about 0.5% to about 10% (w/v) alginate.3. The method according to claim 1 , wherein the first population of cells is present in the first gel at a ...

Method for making a biofabricated material containing collagen fibrils

Described herein is a method for producing a biofabricated material from collagen or collagen-like proteins which are recombinantly produced and which contain substantially no 3-hydroxyproline. The collagen or collagen-like proteins are isolated from animal sources, or produced by recombinant DNA techniques or by chemical synthesis. The collagen or collagen-like proteins are fibrillated, crosslinked, dehydrated and lubricated thus forming the biofabricated material having a substantially uniform network of collagen fibrils.

Composite biofabricated material

The invention is directed to a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrilsand provides strength, elasticity and an aesthetic appearance to the composite material.

IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF

The present invention relates to new immunogenic compositions comprising conjugated capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions. 1Streptococcus pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniae. A kit comprising: (a) a first immunogenic composition comprising at least one glycoconjugate selected from the group consisting of a glycoconjugate from serotype 15B , a glycoconjugate from serotype 22F , a glycoconjugate from serotype 33F , a glycoconjugate from serotype 12F , a glycoconjugate from serotype 10A , a glycoconjugate from serotype 11A and a glycoconjugate from serotype 8 , wherein said composition is a 1 , 2 , 3 , 4 , 5 , 6 or 7-valent pneumococcal conjugate composition; and (b) a second immunogenic composition comprising at least one glycoconjugate from an serotype selected from the group consisting of serotypes 1 , 3 , 4 , 5 , 6A , 6B , 7F , 9V , 14 , 18C , 19A , 19F , and 23F for simultaneous , concurrent , concomitant or sequential administration of the first and second immunogenic compositions.2S. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniaeS. pneumoniae. The kit of claim 1 , wherein said first immunogenic composition comprises a glycoconjugate from serotype 15B claim 1 , a glycoconjugate from serotype 22F claim 1 , a glycoconjugate from serotype 33F claim 1 , a glycoconjugate from serotype 12F claim 1 , a glycoconjugate from serotype 10A claim 1 , a glycoconjugate from serotype 11A and a glycoconjugate from serotype 8 claim 1 , and wherein said composition is a 7-valent ...

Cosmetic Sponge and Method for Providing a Cosmetic Sponge

This invention relates to a cosmetic sponge and a method of providing a cosmetic sponge incorporating a non-denatured collagen and other additives for skin care, cleaning, and cosmetic application. 1. A cosmetic sponge comprising a polymer foam , a non-denatured collagen , and at least one additive.2. The cosmetic sponge of wherein the non-denatured collagen is prepared under pH conditions ranging from approximately 13 to approximately 3.3. The cosmetic sponge or wherein the non-denatured collagen is prepared under pH conditions ranging from approximately 10 to approximately 4.4. The cosmetic sponge of wherein the non-denatured collagen is prepared under pH conditions ranging from approximately 9 to approximately 5.5. The cosmetic sponge of wherein the at least one additive is selected from the group consisting of skin care agents claim 1 , hydrocolloid absorptive agents claim 1 , medicaments claim 1 , proteins claim 1 , enzymes claim 1 , nucleic acids claim 1 , vitamins claim 1 , soaps claim 1 , hemostatic agents claim 1 , antibacterial agents claim 1 , antifungal agents claim 1 , surfactants claim 1 , pH buffers claim 1 , mineral salts claim 1 , trace elements claim 1 , plant extracts claim 1 , animal extracts claim 1 , disinfecting and sterilizing agents claim 1 , and combinations thereof.6. The cosmetic sponge of claim 1 , wherein the sponge is a reaction product of a mixture comprising:a predetermined amount of non-denatured collagen; a predetermined amount of a prepolymer; and at least one additive.7. The cosmetic sponge of wherein the mixture further comprises an agent from the group consisting of: a cross-linking agent claim 1 , a catalyst claim 1 , a surfactant claim 1 , and combinations thereof.8. A method for providing a cosmetic sponge comprising the steps of: forming a mixture comprising non-denatured collagen and water; mixing a prepolymer with said mixture to form a foam layer.9. The method of claim 8 , wherein the non-denatured collagen is prepared ...

SUSTAINED-RELEASE FORMULATION

The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine. 18-. (canceled)10. The sustained release formulation of claim 9 , wherein the weight average molecular weight of the lactic acid polymer claim 9 , or salt thereof claim 9 , is about 13 claim 9 ,000 to about 17 claim 9 ,000.11. The sustained release formulation of claim 10 , wherein the weight average molecular weight of the lactic acid polymer claim 10 , or salt thereof claim 10 , is about 14 claim 10 ,300.12. The sustained release formulation of claim 11 , wherein the sustained-release formulation maintains a pharmaceutically effective blood concentration of the compound claim 11 , or pharmaceutically acceptable salt thereof claim 11 , for about 22 weeks after administration to a subject.13. The sustained-release formulation of claim 12 , wherein the administration is parenteral.14. The sustained release formulation of claim 10 , wherein the weight average molecular weight of the lactic acid polymer claim 10 , or salt thereof claim 10 , is about 16 claim 10 ,000.15. The sustained release formulation of claim 14 , wherein the sustained-release formulation maintains a pharmaceutically effective blood concentration of the compound claim 14 , or pharmaceutically acceptable salt thereof claim 14 , for about 24 weeks after administration to a subject.16. The sustained-release formulation of claim 15 , wherein the administration is ...

METHOD AND DEVICE FOR PRODUCING A CONVERSION PRODUCT, IN PARTICULAR STARCH PASTE

A method for continuously producing a conversion product, in particular starch glue, fried starch, dissolved gelatin or protein glue, wherein a starch-containing and/or protein-containing, preferably powdery starting material, in particular flour, starch powder, cereal grains, coarse cereal meal, gelatin powder or gluten powder, is fed to a mixing chamber () and the starting material, preferably powder, descending in the mixing chamber () is subjected to a liquid heated to a processing temperature (T) of at least 50° C. for converting the starting material into the conversion product, in particular to at least a gelatinization temperature of the starch-containing starting material, a protein-dissolving and/or denaturing temperature of the protein-containing starting material or a frying temperature, in the form of a pressure jet () and is thereby conveyed against a baffle () preferably formed by an inner wall of the mixing chamber or by an installation in the mixing chamber. 122710. +A method for continuously producing a conversion product , in particular starch glue , fried starch , dissolved gelatin or protein glue , wherein a starch-containing and/or protein-containing , preferably powdery starting material , in particular flour , starch powder , cereal grains , coarse cereal meal , gelatin powder or gluten powder , is fed to a mixing chamber () and the starting material , preferably powder , descending in the mixing chamber () is subjected to a liquid heated to a processing temperature (T) of at least 50° C. for converting the starting material into the conversion product , in particular to at least a gelatinization temperature of the starch-containing starting material , a protein-dissolving and/or denaturing temperature of the protein-containing starting material or a frying temperature , in the form of a pressure jet () and is thereby conveyed against a baffle () preferably formed by an inner wall of the mixing chamber or by an installation in the mixing ...

Novel biofabrication techniques for the implementation of intrinsic tissue geometries to an in vitro collagen hydrogel

Methods for reaction electrospinning are provided to form collagen fibers. The method can include: acidifying a collagen in an acidic solvent to form an acidic collagen solution; electrospinning the acidic collagen solution within an alkaline atmosphere (e.g., including ammonia vapor) to form collagen fibers; and collecting the collagen fibers within a salt bath (e.g., including ammonium sulfate). The acidic solvent can include water and an alcohol, and can have a pH of about 2 to about 4 (e.g., including a strong acid, such as HCl). An albumin rubber is also provided, which can include albumin crosslinked with glutaraldehyde.